0001317833 false Q3 2022 --12-31 0001317833 2022-01-01 2022-09-30 0001317833 2022-11-14 0001317833 2022-09-30 0001317833 2021-12-31 0001317833 AQPW:ConvertibleSeriesAPreferredStockMember 2022-09-30 0001317833 AQPW:ConvertibleSeriesAPreferredStockMember 2021-12-31 0001317833 2022-07-01 2022-09-30 0001317833 2021-07-01 2021-09-30 0001317833 2021-01-01 2021-09-30 0001317833 us-gaap:PreferredStockMember AQPW:ConvertibleSeriesAPreferredStockMember 2021-12-31 0001317833 us-gaap:CommonStockMember 2021-12-31 0001317833 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001317833 us-gaap:RetainedEarningsMember 2021-12-31 0001317833 us-gaap:PreferredStockMember AQPW:ConvertibleSeriesAPreferredStockMember 2020-12-31 0001317833 us-gaap:CommonStockMember 2020-12-31 0001317833 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001317833 us-gaap:RetainedEarningsMember 2020-12-31 0001317833 2020-12-31 0001317833 us-gaap:PreferredStockMember AQPW:ConvertibleSeriesAPreferredStockMember 2022-01-01 2022-09-30 0001317833 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001317833 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001317833 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001317833 us-gaap:PreferredStockMember AQPW:ConvertibleSeriesAPreferredStockMember 2021-01-01 2021-09-30 0001317833 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001317833 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001317833 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001317833 us-gaap:PreferredStockMember AQPW:ConvertibleSeriesAPreferredStockMember 2022-09-30 0001317833 us-gaap:CommonStockMember 2022-09-30 0001317833 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001317833 us-gaap:RetainedEarningsMember 2022-09-30 0001317833 us-gaap:PreferredStockMember AQPW:ConvertibleSeriesAPreferredStockMember 2021-09-30 0001317833 us-gaap:CommonStockMember 2021-09-30 0001317833 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001317833 us-gaap:RetainedEarningsMember 2021-09-30 0001317833 2021-09-30 0001317833 AQPW:SeriesAConvertibleSuperPreferredStockMember AQPW:SharePurchaseAndExchangeAgreementMember 2022-09-30 0001317833 us-gaap:CommonStockMember AQPW:SharePurchaseAndExchangeAgreementMember 2022-09-30 0001317833 us-gaap:CommonStockMember AQPW:SharePurchaseAndExchangeAgreementMember 2022-01-01 2022-09-30 0001317833 AQPW:SharePurchaseAndExchangeAgreementMember 2022-01-01 2022-09-30 0001317833 AQPW:LegalServiceMember 2022-01-01 2022-09-30 0001317833 AQPW:LegalServiceMember 2022-09-30 0001317833 srt:DirectorMember 2022-09-30 0001317833 srt:OfficerMember 2022-09-30 0001317833 2022-05-15 0001317833 2022-06-01 0001317833 AQPW:TwelveMonthsEndedSeptemberThirtyTwoThousandTwentyThreeMember 2022-09-30 0001317833 AQPW:TwelveMonthsEndedSeptemberThirtyTwoThousandTwentyFourMember 2022-09-30 0001317833 AQPW:AsiaHybridCryptocurrencyLimitedMember 2021-12-01 0001317833 AQPW:AsiaHybridCryptocurrencyLimitedMember 2021-11-30 2021-12-01 0001317833 2022-04-06 0001317833 us-gaap:SeriesAPreferredStockMember 2022-04-06 0001317833 us-gaap:SeriesAPreferredStockMember 2022-09-30 0001317833 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001317833 2021-01-01 2021-12-31 0001317833 stpr:TX 2022-01-01 2022-09-30 0001317833 country:CA 2022-01-01 2022-09-30 0001317833 AQPW:LoanAgreementMember 2022-05-15 0001317833 AQPW:LoanAgreementMember 2022-05-14 2022-05-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2022

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ________to________

 

Commission File No. 000-51185

 

Golden Ally Lifetech Group, Inc.

(exact name of registrant as specified in its charter)

 

Delaware   16-1732674

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification Number)

 

901 S. Mopack Exp Building 1, Suite 300, Austin, TX 78746

(Address of principal executive offices) (zip code)

 

(512) 430-1553

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
         

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   Accelerated Filer
Non-accelerated filer   Smaller reporting company
Emerging growth company      

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

As of November 14, 2022, the registrant had 8,496,061,902 shares of common stock outstanding.

 

 

 

 

 

 

Table of Contents

 

    Page
     
PART I. FINANCIAL INFORMATION  
     
Item 1. Financial Statements (unaudited) 3
     
  Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021 3
     
  Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2022 and 2021 4
     
  Condensed Consolidated Statements of Stockholders’ Equity (Deficit) as of September 30, 2022 and 2021 5
     
  Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2022 and 2021 6
     
  Notes to Condensed Consolidated Financial Statements 7
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 11
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 13
     
Item 4. Controls and Procedures 13
     
PART II. OTHER INFORMATION  
     
Item 1. Legal Proceedings 14
     
Item 1A. Risk Factors 14
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 14
     
Item 3. Defaults Upon Senior Securities 14
     
Item 4. Mine Safety Disclosures 14
     
Item 5. Other Information 14
     
Item 6. Exhibits 14
     
SIGNATURES 15

 

2

 

 

Item 1. Financial Statements.

 

Golden Ally Lifetech Group, Inc.

Condensed Consolidated Balance Sheets

 

   September 30, 2022   December 31, 2021 
   (Unaudited)  

(Audited)

 
Assets          
           
Current          
Cash  $1,426,467   $2,999,370 
Prepaids   280,471    - 
Loan receivable - related party   1,000,000    - 
Total Current Assets   2,706,938    2,999,370 
           
Right of use asset   115,175    - 
Goodwill   1,777,204    - 
Total Assets  $4,599,317   $2,999,370 
           
Liabilities and Stockholders’ Equity          
Current Liabilities          
Accounts payable and accrued liabilities  $22,124   $- 
Lease liabilities   67,939    - 
Due to related parties   5,000    5,000 
Total Current liabilities   95,063    5,000 
           
Lease liability, net of current portion   49,026    - 
Total Liabilities   144,089    5,000 
           
Stockholders’ Equity          
           
Convertible Series A Preferred Stock, par value $0.00001: 1,000,000,000 authorized; 1,000,000,000 and 5,000,000 outstanding   10,000    50 
Common Stock, par value $0.00001; 10,000,000,000 authorized; 8,496,061,902, and 20,535,982 outstanding   84,961    205 
Additional paid-in capital   9,402,893    3,051,685 
Accumulated deficit   (5,042,626)   (57,570)
Total Stockholders’ Equity   4,455,228    2,994,370 
           
Total Liabilities and Stockholders’ Equity  $4,599,317   $2,999,370 

 

See accompanying notes to financial statements.

 

3

 

 

Golden Ally Lifetech Group, Inc.

Condensed Consolidated Statements of Operations

For the Three and Nine Months Ended September 30, 2022 and 2021

(Unaudited)

 

   2022   2021   2022   2021 
   For the Three Months Ended
September 30,
   For the Nine Months Ended
September 30,
 
   2022   2021   2022   2021 
                 
Operating Expenses                    
General and administrative   54,218    -    212,266    - 

Professional fees

   926,213    -    3,427,745    - 
Research and development   -         18,450      
Wages and salaries   438,037    -    1,326,595    - 
                     
Total Operating Expenses   1,418,468         4,985,056    - 
                     
Net operating loss  $(1,418,468)  $-    (4,985,056)   - 
Income tax   -    -    -    - 
Net Loss  $(1,418,468)  $-   $(4,985,056)  $- 
                     
Loss per Common Share  $(0.00)  $-   $(0.00)  $- 
                     
Weighted Average Common Shares Outstanding   8,475,525,920    20,535,982    5,526,167,083    20,535,982 

 

See accompanying notes to financial statements.

 

4

 

 

Golden Ally Lifetech Group, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

For the Three and Nine Months Ended September 30, 2022 and 2021

(Unaudited)

 

   Shares   Amount   Shares   Amount   Capital   Deficit   Total 
   Convertible Series A Preferred Stock   Common Stock  

Additional

Paid-in

   Accumulated     
   Shares   Amount   Shares   Amount   Capital   Deficit   Total 
                             
Balance December 31, 2021   5,000,000   $50    20,535,982   $205   $3,051,685   $(57,570)  $2,994,370 
Stock subscription received   -    -    -    -    5,042,060         5,042,060 
Recapitalization (reverse merger)   -    -    -    -    1,777,204    -    1,777,204 
Issuance of stock   995,000,000    9,950    8,475,525,920    84,755    (94,705)   -    - 
Share exchange (reverse merger)                       (373,350)   -    (373,350)
Net loss   -    -    -    -    -    (4,985,056)   (4,985,056)
Balance September 30, 2022   1,000,000,000   $10,000    8,496,061,902   $84,961   $9,402,893   $(5,042,626)  $4,455,228 

 

   Convertible Series A Preferred Stock   Common Stock  

Additional

Paid-in

   Accumulated     
   Shares   Amount   Shares   Amount   Capital   Deficit   Total 
                             
Balance December 31, 2020   -   $-    -   $-   $-   $-   $- 
Net loss   -    -    -    -    -    -    - 
Balance September 30, 2021        -   $       -          -   $        -   $        -   $         -   $     - 

 

See accompanying notes to financial statements.

 

5

 

 

Golden Ally Lifetech Group Inc.

Condensed Consolidated Statements of Cash Flows

For the Nine Months Ended September 30, 2022 and 2021

(Unaudited)

 

   2022   2021 
   For the Nine Months Ended
September 30,
 
   2022   2021 
CASH FLOWS FROM OPERATING ACTIVITIES          
           
Net loss  $(4,985,056)  $       - 
Adjustments to reconcile net loss to net cash used in operating activities:          
Amortization of ROU asset   23,035    - 
Payment of lease lability   

(21,245

)   - 
Prepaids   (280,471)   - 
Accounts payable and accrued liabilities and other   22,124    - 
Net cash used in Operating Activities   (5,241,613)   - 
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Proceeds from issuance of common shares   5,042,060    - 
Net cash provided by Financing Activities   5,042,060    - 
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Share exchange (reverse merger)   (373,350)   - 
Loan receivable - related party   (1,000,000)   - 
Net cash provided by Investing Activities   (1,373,350)   - 
           
Inflow of Cash   (1,572,903)   - 
Cash - Beginning of period   2,999,370    - 
Cash - End of period  $1,426,467   $- 
           
SUPPLEMENTAL CASH FLOW INFORMATION:          
Cash paid for income taxes  $-   $- 
Cash paid for interest  $-   $- 
           
NON CASH INVESTING AND FINANCING ACTIVITIES:          
Value of shares not exchanged in reverse merger  $1,403,854      

 

See accompanying notes to financial statements.

 

6

 

 

Golden Ally Lifetech Group, Inc.

Condensed Consolidated Notes to Unaudited Financial Statements

September 30, 2022

 

NOTE 1 – BUSINESS

 

Golden Ally Lifetech Group, Inc. (“Golden Ally”) is a Delaware corporation incorporated on December 1, 2020, and operates out of Austin, Texas.

 

Golden Ally is a start-up focusing on a unique product offering. Golden Ally activities to date have focused on the development and exploration of water filtration technology and consumer products with Aquaporin (“AQP”) Bottled Water. Golden Ally has been working with field experts and research institutions to apply and explore the ability to enhance water filtration for improved body cell absorption in commercialized water products.

 

On April 06, 2022, Golden Ally closed on the Share Purchase and Exchange Agreement (“SPA”) with Signet International Holdings, Inc. (“Signet”), a Delaware corporation formed on February 2, 2005, and the Signet Controlling Shareholders. Under generally accepted accounting principles, the acquisition by Signet of Golden Ally is considered to be a capital transaction in substance, rather than a business combination. That is, the acquisition is equivalent to the acquisition by Golden Ally of Signet with the issuance of stock by Golden Ally for the net assets of Signet. This transaction is reflected as a recapitalization and is accounted for as a change in capital structure. Accordingly, the accounting for the acquisition is identical to that resulting from a reverse acquisition. Under reverse merger accounting, the comparative historical financial statements of Signet, as the legal acquirer, are those of the accounting acquirer, Golden Ally. Accordingly, Golden Ally’s financial statements prior to the closing of the reverse acquisition, reflect only the business of Golden Ally. Under the SPA, the Controlling Shareholders of Signet agreed to sell to the Company their capital stock of the Company, consisting of 5,000,000 shares of Series A Convertible Super Preferred Stock (convertible into 50,000,000 common shares) and 4,474,080 common shares for $375,000‎ in cash.

 

In March 2022 Signet’s Board of Directors approved, among other things, an Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, subject to stockholder approval. Stockholder approval was obtained through written consent. Upon approval of all applicable regulatory authorities, Signet’s name was changed from “Signet International Holdings, Inc.” to “Golden Ally Lifetech Group, Inc.”

 

NOTE 2 – GOING CONCERN

 

The financial statements have been prepared on a going concern basis which assumes Golden Ally will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. Golden Ally has not yet established a source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. As reflected in the accompanying unaudited condensed financial statements, Golden Ally had a net loss of $4,985,056 and used net cash in operations of $5,241,613 for the nine months ended September 30, 2022. Golden Ally has an accumulated deficit of $5,042,626 as of September 30, 2022. These factors raise substantial doubt about the ability of Golden Ally to continue as a going concern.

 

In order to continue as a going concern, Golden Ally will need, among other things, additional capital resources. Management’s plan is to obtain such resources for Golden Ally by obtaining capital from management and significant shareholders sufficient to meet its minimal operating expenses and seeking third party equity and/or debt financing.

 

Management has held preliminary discussions with potential investors to secure significant capital for Golden Ally in 2022. Management believes that the diversified options for financing potentially available to Golden Ally, along with support from significant shareholders, will allow it to achieve its objectives and satisfy its capital requirements.

 

These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should Golden Ally be unable to continue as a going concern.

 

7

 

 

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited condensed financial statements have been prepared in accordance with GAAP and applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for quarterly reports on Form 10-Q and Article 8 of Regulation S-X. Accordingly, certain information and footnotes required by GAAP in annual financial statements have been omitted or condensed and these interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in Signet’s Information Statement on Schedule 14C, filed with the SEC on March 16, 2022. These condensed financial statements of Golden Ally include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of the Golden Ally’s financial position as of September 30, 2022, and results of its operations and its cash flows for the interim periods presented. The results of operations for the nine months ended September 30, 2022, are not necessarily indicative of the results to be expected for the entire year. There have been no significant changes in the Golden Ally’s accounting policies from those described in the Golden Ally’s audited financial statements and the related notes to those statements.

 

Pursuant to the SPA, the Business Combination was accounted for as a recapitalization in accordance with US GAAP. Under this method of accounting, of Signet International Holdings, Inc., was treated as the acquired company and Golden Ally Lifetech Group, Inc., was treated as the acquirer for financial statement reporting purposes.

 

Golden Ally Lifetech Group, Inc. was determined to be the accounting acquirer based on evaluation of the following facts and circumstances:

 

  Golden Ally Lifetech Group, Inc., through their ownership of the Convertible Series A Preferred stock and Common Stock, has a 77% of the voting interest;
     
  Golden Ally Lifetech Group, Inc., selected all of the new board of directors of Signet;
     
  Golden Ally Lifetech Group, Inc., senior management is the senior management of Signet; and
     
  Golden Ally Lifetech Group, Inc., is the larger entity based on historical operating activity.

 

Use of Estimates

 

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and disclosure at the date of the financial statements. Actual results could differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for continued reasonableness. Actual results and outcomes may differ from management’s estimates and assumptions.

 

Cash and cash equivalents

 

For purposes of the statement of cash flows, Golden Ally considers all highly liquid instruments purchased with an original maturity of three months or less to be cash.

 

As of September 30, 2022, and December 31, 2021, Golden Ally had cash of $1,426,467 and $2,999,370.

 

Concentrations of Credit Risk

 

Golden Ally maintains its cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. Golden Ally continually monitors its banking relationships and consequently has not experienced any losses in its accounts. Management believes Golden Ally is not exposed to any significant credit risk on cash.

 

Loss per Share

 

Loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Golden Ally had no dilutive instruments outstanding during the periods presented.

 

8

 

 

Recent Accounting Pronouncements

 

Golden Ally has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and Golden Ally does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations

 

NOTE 4 – PREPAID EXPENSE

 

During the nine months ended September 30, 2022, Golden Ally entered into an agreement for legal services and paid $750,000 as a retainer to the legal service provider. As of September 30, 2022, $522,983 of the retainer was expensed and the $227,017 was recorded as a prepaid expense.

 

During the three months ended September 30, 2022, the Company prepaid for director and officer insurance for a twelve-month period for $58,038 and commercial insurance for a period of twelve months for $3,826. As of September 30, 2022, $8,410 was expensed in relation to insurance.

 

NOTE 5 – LOAN RECEIVABLE – RELATED PARTY

 

On May 15, 2022, the Company entered into a loan agreement whereby the Company loaned $1,000,000 to a related party to support working capital needs and to support a potential partnership in the future. The loan is interest free and matures on November 14, 2022.

 

NOTE 6 - LEASES

 

During the nine months ended September 30, 2022, the Company entered into a lease for a location in California. The lease commenced on June 1, 2022 and is for a period of two years. The Company has accounted for the lease in accordance with ASC 842, Leases. Upon commencement of the lease, the Company recorded a right of use asset and lease liability for $138,210. During the nine months ended September 30, 2022, the Company recognized $23,035 in amortization, $3,955 in interest expense and made payments of $25,200 on the lease liability. As at September 30, 2022, the right of use asset was $115,175 and the lease lability was $116,965. The discount rate used in the calculation was 10% based on industry comparable rates.

 

The principal lease payments are as follows:

 

           
    12 Months Ended September 30,
   2023   2024 
Lease Costs   75,600    50,400 
Imputed Interest   -7,661    -1,374 
Total   67,939    49,026 

 

NOTE 7 – GOODWILL

 

Under generally accepted accounting principles, the acquisition by Signet of Golden Ally is considered to be a capital transaction in substance, rather than a business combination. That is, the acquisition is equivalent to the acquisition by Golden Ally of Signet with the issuance of stock by Golden Ally for the net assets of Signet. This transaction is reflected as a recapitalization and is accounted for as a change in capital structure. Accordingly, the accounting for the acquisition is identical to that resulting from a reverse acquisition. Under reverse merger accounting, the comparative historical financial statements of Signet, as the legal acquirer, are those of the accounting acquirer, Golden Ally. As part of the agreement, Golden Ally exchanged 100% of its shares for 77% of Signet shares, representing a premium for the 23% of Signet stock not acquired. Golden Ally recorded $1,777,204 in Goodwill for the shares not acquired and $375,000 cash paid.

 

NOTE 8 – INVESTMENT – RELATED PARTY, AND ITS SUBSEQUENT RECISSION

 

On December 1, 2021, the Company entered into an agreement to purchase 20% of the issued and outstanding shares of Asia Hybrid Cryptocurrency Company Limited (“Asia Hybrid”) for $2,000,000. As part of the agreement, Asia Hybrid was to develop and maintain a digital platform for use by the Company. The Company made the payment of $2,000,000 in accordance with the agreement in December 2021.

 

On March 7, 2022, the Company entered a recission agreement with Asia Hybrid, and a related party, whereby the original agreement between the Company and Asia Hybrid was rescinded effective December 1, 2021, and both party’s obligations of the agreement were terminated.

 

NOTE 9 – CAPITAL STOCK

 

Common Stock

 

During the nine months ended September 30, 2022, Golden Ally received $5,042,060 for stock subscriptions related to common stock.

 

During the nine months ended September 30, 2022, the Company issued 8,475,525,920 shares of common stock as part of the recapitalization transaction that occurred during the period.

 

9

 

 

The authorized capital stock consists of 10,000,000,000 shares of common stock at par value of $0.00001. There were 8,496,525,920 and 20,535,920 common shares outstanding as of September 30, 2022 and December 31, 2021.

 

Preferred stock

 

On April 6, 2022, the Company amended the authorized shares of capital preferred stock to 1,000,000,000 with a par value of $0.00001.

 

On April 6, 2022, the Company issued 995,000,000 shares of Series A Preferred Stock in connection with the transaction effected pursuant to the SPA generally described in Note 1.

 

There were 1,000,000,000 and 5,000,000 shares of Series A preferred stock issued and outstanding as of September 30, 2022, and December 31, 2021.

 

On July 8, 2022, the Company merged its sole subsidiary into the Company. Only the Company exists from this date.

 

NOTE 10 – RELATED PARTIES

 

During the year ended December 31, 2021, a related party paid expenses on behalf of the Company of $5,000. As of September 30, 2022, the related party owed $5,000.

 

During the nine months ended September 30, 2022 and 2021, the Company paid $1,233,964 and $nil, respectively, in wages and salaries to related parties.

 

During the nine months ended September 30, 2022, Golden Ally entered into an agreement with a company owned by a related party to develop and implement marketing strategies for Golden Ally’s products. Golden Ally paid $2,650,000 per the terms of the agreement for services to be provided, which have been included in Professional fees. The Company does not have any further obligations or commitments to incur additional expenses with this related party.

 

See Note 5 for Loan Receivable – Related Party.

 

NOTE 11 – COMMITMENTS

 

Operating lease

 

During the nine months ended September 30, 2022, the Company entered into an agreement for office space in Texas. The agreement term is from January 19, 2022, to January 31, 2023 at a rate of $332 per month. The lease has been accounted for as a short-term lease and rental payments expensed.

 

During the nine months ended September 30, 2022, the Company entered into a lease for a location in California. The term of the lease was four months ending on May 31, 2022. The base rent is $6,300 per month. The lease was been accounted for as a short-term lease and rental payments expensed. The lease was renewed on June 1, 2022 and has been accounted for in accordance with ASC 842, Leases.

 

NOTE 12 – SUBSEQUENT EVENTS

 

On May 15, 2022, the Company entered into a loan agreement whereby the Company loaned $1,000,000 to a related party. The loan is interest free and matured on November 14, 2022. The Company is currently negotiating an extension of the loan agreement and has not received the full proceeds of the loan as of the date of this filing.

 

END OF FINANCIAL STATEMENTS

 

10

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

You should read the following discussion and analysis together with our financial statements and the notes to those statements included elsewhere in this Quarterly Report on Form 10-Q and other reports we filed with the Securities and Exchange Commission. This Quarterly Report on Form 10-Q contains statements that discuss future events or expectations, projections of results of operations or financial condition, trends in our business, business prospects and strategies and other “forward-looking” information. In some cases, you can identify “forward-looking statements” by words like “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “intends,” “potential” or “continue” or the negative of those words and other comparable words. These statements may relate to, among other things, our ability to implement and fund our business plan; expectations for our financial results, revenue, operating expenses and other financial measures in future periods; and the adequacy of our sources of liquidity to satisfy our working capital needs, capital expenditures, and other liquidity requirements.

 

April 2022 Reverse Merger (Purchase); Recent Developments

 

On February 28, 2022, Signet International Holdings, Inc. (“Signet”),‎ Estate of Ernest W. Letiziano, Ms. Hope Hillabrand, and Mr. Thomas Donaldson ‎‎(collectively, the “Controlling Shareholders”) and Golden Ally Lifetech Group Co., Ltd., a Delaware corporation (“Golden Ally”) entered into a Share Purchase and Exchange Agreement (the “SPA”).

 

Under the SPA, the Controlling Shareholders agreed to exchange their capital stock of Signet, consisting of 5,000,000 shares of Series A Convertible Super Preferred Stock (convertible into 50,000,000 common shares), 4,474,080 common shares, and $375,000‎ cash for all the shares of Golden Ally (the “Purchase”).

 

The Purchase contemplated by the SPA was consummated on April 6, 2022. Immediately after the Closing, the former stockholders of Golden Ally Sub collectively hold beneficially and of record over 99% of the total issued and outstanding equity securities and voting power of Signet. The Purchase resulted in Golden Ally becoming a subsidiary of Signet and the shareholders of Golden Ally holding shares of Signet.

 

In March 2022 Signet’s Board of Directors approved, among other things, an Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, subject to stockholder approval. Stockholder approval was obtained through written consent. On July 8, 2022, Golden Ally was merged with and into Signet and Signet’s name was from “Signet International Holdings, Inc.” to “Golden Ally Lifetech Group, Inc.” In this report references to “Golden Ally” or the “Company” refer to the operations and assets of the Company on a post-purchase basis.

 

Our Business

 

Golden Ally is focused on its Aquaporin (“AQP”) Bottled Water project, which is a derivative of an academic inspiration from the 2003 Nobel Laureates in Chemistry, Dr. Peter Agre and Dr. Roderick MacKinnon jointly, “for discoveries concerning channels in cell membranes”. Golden Ally has been working closely with experienced field experts and top scientific research institutions to apply the famous Nobel Prize theory of aquaporins into its commercialized products, i.e., the AQP Bottled Water.

 

AQP Bottled Water is the product of a unique water filtration technology derived from raw materials with exclusive access by Golden Ally. The advanced technology can enhance water filtration for better body cell absorption to improve health. All AQP Bottled Water products are expected to be produced through OEM arrangements and their distribution logistics will also be supported by the OEM partners.

 

AQP Bottled Water is an epoch-making product. . Golden Ally has been running laboratory tests on its products at the David Geffen School of Medicine at University of California, Los Angeles.

 

High-income households are Golden Ally’s targeted consumers due to a strong correlation between income level and health spending. The global consumer pool for AQP Bottled Water is estimated at 17.61 million households. These households represent the portion that has an annual household income of over $150,000 USD, a level that can potentially support annual household spending on healthcare products.

 

11

 

 

Results of Operations

 

Overview

 

Golden Ally is a developmental stage company that is currently implementing its business plan, which is to be a high-tech start-up focused on a unique product offering. Our activities to date have focused on the development and exploration of water filtration technology and consumer products with AQP Bottled Water. We have been working with field experts and research institutions to apply and explore the ability to enhance water filtration for improved body cell absorption in commercialized water products. During the quarter ended September 30, 2022, the Company continued taking steps to implement its business plan, including negating various agreements related to the production, marketing and distribution of its products, including a Supplier Agreement with Taucoin Asset Management, LLC and a Strategic Alliance Agreement with Taucoin Asset Management, LLC

 

Limited Operating History; Need for Additional Capital

 

We have had limited operations and have been issued a “going concern” opinion by our auditor for the year ended December 31, 2021, based on our lack of an established source of revenues sufficient to cover our operating costs and allow us to continue as a going concern. As of September 30, 2022, we have incurred a cumulative deficit of $5,042,626. There is limited historical financial information about us upon which to base an evaluation of our performance. We have not generated any revenues from operations. We cannot guarantee that we will be successful in our business operations.

 

Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources, possible delays in developing our products and market downturns.

 

In the nine months ended September 30, 2022, Golden Ally received $5,042,000 for stock subscriptions receivable related to its Common Stock. We expect to require further outside sources of liquidity and have no assurance that future financings will be available to us on acceptable terms, or at all. If financing is not available on satisfactory terms, we may be unable to continue, develop or expand our operations. Equity financing could result in additional dilution to existing shareholders. If we are unable to raise additional capital to maintain our operations in the future, we may be unable to carry out our business plans or we may be forced to cease operations.

 

Going Concern

 

Our financial statements have been prepared on a going concern basis which assumes Golden Ally will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. No revenues have been generated to date and we expect limited revenues.

 

Results of Operations

 

During the three and nine months ended September 30, 2022, we did not generate any revenue. Our operating expenses for the three and nine month periods ended September 30, 2022 were $1,418,468 and $4,985,056, consisting primarily of professional fees and other expenses paid to continue to develop and implement marketing strategies for its products and wages and salaries for Company personnel. As a result, for the three and nine months ended September 30, 2022, we incurred a loss from operations of $1,418,468 and $4,985,056. During the three and nine months ended September 30, 2021, we did not have any operations.

 

Liquidity and Capital Resources

 

Working Capital and Cash Flows. Golden Ally used cash of $5,241,613 for‎ operating activities for the nine months ended September 30, 2022.

 

On January 3, 2022, Golden Ally entered into an agreement with a company owned by a related party, Taucoin Asset Management LLC, to develop and implement marketing strategies for its products and paid $1,000,000 on January 12, 2022, per the terms of the agreement for services, and subsequently another $200,000 was paid.

 

On January 18, 2022, Golden Alley entered into an agreement for legal services. In January 2022, Golden Ally paid $500,000 as a retainer to the legal service provider.

 

12

 

 

Golden Ally has a lease for an office in Texas for one year at $332 per month. During the nine months ended September 30, 2022, the Company also entered into a lease for a location in California. The initial term of the lease was four months ending on May 31, 2022. The lease was renewed on June 1, 2022, and the base rent is currently $6,300 per month.

 

In July 2022, the Company paid a related party, Taucoin Asset Management LLC, additional amounts of $200,000 and $400,000 to develop and implement marketing strategies for Company products.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material to investors.

 

Critical Accounting Policies

 

Our financial statements and related public financial information are based on the application of accounting principles generally accepted in the United States (“GAAP”). GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that affect the reported amounts of assets and liabilities, revenues and expenses and related disclosures in our financial statements. We had no critical accounting policies for the year ended December 31, 2021, or for the quarter ended September 30, 2022.

 

We have other key accounting policies, which involve the use of estimates, judgments and assumptions that are significant to understanding our results, which are summarized in Note 3 to our financial statements. Although we believe that our estimates, judgments and assumptions are reasonable, they are based upon information presently available. Actual results may differ from those estimates.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

 

Item 4. Controls and Procedures

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our periodic reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such information is collected and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our Chief Executive Officer and Chief Financial Officer are responsible for establishing and maintaining disclosure controls and procedures for our Company. In designing and evaluating our disclosure controls and procedures, management recognizes that no matter how well conceived and operated, disclosure controls and procedures can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met.

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, carried out an evaluation of the effectiveness of our “disclosure controls and procedures” (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Quarterly Report on Form 10-Q (the “Evaluation Date”). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of the Evaluation Date, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported, within the time periods specified in the SEC rules and forms and (ii) is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting during the quarter ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

13

 

 

PART II.

 

Item 1. Legal Proceedings

 

None.

 

Item 1A. Risk Factors

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

N/A

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

Item 6. Exhibits

 

EXHIBIT NO.   DESCRIPTION
10.1   Supplier Agreement between Golden Ally Lifetech Group, Inc. and Taucoin Asset Management, LLC dated July 12, 2022
10.2+   Strategic Alliance Agreement between Golden Ally LifeTech Group, Inc. and Taucoin Asset Management, LLC dated July 12, 2022
31.1*   Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*   Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**   Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

 

* Furnished herewith.

 

** The certifications attached as Exhibits 32.1 and 32.2 that accompanies this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

 

+ Certain portions of this agreement have been omitted because such information is not material and is the type that the registrant treats as private or confidential.

 

14

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Date: November 21, 2022   Golden Ally Lifetech Group, Inc.
         
      By: /s/ Oliver Keren Ban                            
        Oliver Keren Ban, Chief Executive Officer and President (Principal Executive Officer), Secretary, Treasurer, and Director
         
      By: /s/ Tak Yiu Cheng
        Tak Yiu Cheng, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

 

15

 

Exhibit 10.1

 

SUPPLIER AGREEMENT

 

This Supplier Agreement (“Agreement”) is dated July 12, 2022, by and between Taucoin Asset Management, LLC, a Delaware limited liability company (“TCAM”), and Golden Ally LifeTech Group, Inc., a Delaware corporation (“Supplier” or “GALT”, and together with Supplier, the “Parties”, and each a “Party”). This Agreement includes each of the Orders entered into pursuant to this Agreement which are hereby incorporated into and deemed part of this Agreement.

 

RECITALS:

 

WHEREAS, Supplier is in the business of developing, manufacturing, and distributing certain goods and materials related to its proprietary AQP water products globally (the “AQP Products”);

 

WHEREAS, TCAM is developing a blockchain-based technology platform (the “Platform”) to facilitate sales of the AQP Products; and

 

WHEREAS, the Parties desire to enter into this Agreement whereby Supplier will provide AQP Products for TCAM, and TCAM will purchase Products from Supplier as described herein.

 

NOW THEREFORE, in consideration of the mutual promises and agreements contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

 

1. Certain Defined Terms.

 

For purposes of this Agreement, the following terms shall have the meanings set forth below:

 

Affiliates” means any legal entity that owns or controls, is owned or controlled by, or is under common ownership or control with, the relevant Party.

 

Fees” means the fees payable to Supplier for the AQP Products, as set forth in an Order.

 

GALT Material” means such items provided or made available by GALT, including but not limited to the following: (a) any and all proprietary information or specifications of GALT and the AQP Products, including, without limitation certain proprietary inventions, raw materials, and formulas relating to the extraction from, separation, and processing of certain ingredients to manufacture and produce AQP Products and (b) any and all drawings, specifications, toolings, concepts, designs, technology, and/or materials to practice and use in conjunction with the formulation, cultivation, development, production, and distribution of the AQP Products.

 

GALT Standards” means, collectively, a set of criteria to which the AQP Products must adhere and may include, without limitation: (a) the production and quality control standards, manufacturing and development processes, and packaging, shipping, and labeling specifications or requirements; (b) any applicable regulatory, environmental, health, and safety standards or requirements; and (c) any other qualitative or quantitative requirements or additional terms and conditions specified in the applicable Order; and, with respect to each of the foregoing, as may be supplemented, modified, or replaced by TCAM or the respective TCAM Party, as applicable.

 

1

 

 

Intellectual Property Rights” means all current and future worldwide patents and other patent rights, utility models, copyrights, mask works, know-how, trade secrets, and all other intellectual property rights and the related documentation or other tangible expression thereof.

 

New Intellectual Property” means all tangible and intangible results and items arising out of or constituting the results of any development work created pursuant to the Agreement, and all Intellectual Property Rights constituting, embodied in, or pertaining to any of the foregoing.

 

Order” means an ordering document issued by TCAM, including any addenda, amendments and supplements thereto. For the avoidance of doubt, any references to Orders hereunder also include any applicable Purchase Orders (as hereinafter defined).

 

Taxes” means any and all value-added, sales, excise, custom, use or other taxes (whether federal, state or local), assessments, fees or duties arising as a result of TCAM’s purchase from Supplier or Supplier’s manufacture, performance or sale of the Products. Taxes includes, without limitation, any tax, assessment, fee or duty measured or imposed upon Supplier’s income, payroll or property and any franchise tax.

 

TCAM Party” means any applicable customers, subcontractors, purchasers, or representatives of TCAM or its Affiliates.

 

2. Manufacture and Supply of the AQP Products.

 

(a)   Supply of the Products. Supplier shall produce the AQP Products pursuant to the GALT Standards and in accordance with the quality assurance protocols approved by TCAM.

 

(b)   Ingredients and Materials Disclosure. Upon request, Supplier shall promptly provide to TCAM, in such form and detail as TCAM requests, a list of all ingredients and materials incorporated in the AQP Products, the amount of such ingredients and materials, and any information concerning any changes in or additions to such ingredients and materials.

 

(c)   Manufacturing Components. Unless otherwise expressly agreed in the applicable Order, Supplier may not charge TCAM for the cost of formulating or procuring of any equipment, tools or other items or materials used in the development, manufacture, or supply of the AQP Products (the “Manufacturing Components”). Supplier shall, at its sole expense, keep in good condition and replace as necessary all Manufacturing Components.

 

(d)    Supplier Restrictions. Supplier shall: (a) not, and shall not permit any third party to access or use the GALT Materials or AQP Products to develop or manufacture any offering, service, or product directly or indirectly competing with any offering or product of TCAM or (b) communicate with any TCAM Party other than through the designated contact set forth on the Order. Nothing herein shall be deemed to prevent or restrict TCAM in any manner whatsoever from furnishing, granting, or contracting with any other entity to furnish any goods that may be similar to the AQP Products.

 

(e)    Compliance with GALT Standards. GALT will have final authority to promulgate GALT Standards and to modify or grant waivers from such GALT Standards in its sole discretion. TCAM hereby acknowledges and agrees that the GALT Materials may be owned by third parties, and that in order to access and use such GALT Materials or to supply the AQP Products, Supplier may be required to agree (by one or more agreements in paper or electronic form) to abide by any additional terms and conditions imposed by third parties. Supplier agrees to (a) enter into any further written agreements as requested by TCAM; and (b) obtain TCAM’s prior written approval for any deviations from such GALT Standards. If and to the extent of any conflict between this Agreement and any such GALT Standards, such GALT Standards will control for the purposes of the applicable AQP Products only.

 

2

 

 

(f)    Government Approval. If at any time during the Term any notification, registration, or approval is required for giving legal effect in any applicable jurisdiction to this Agreement or the transactions contemplated under this Agreement, Supplier shall: (a) immediately take whatever steps that may be necessary to properly notify, register or obtain approval; (b) be responsible for any charges incurred in connection with notifying, registering or obtaining this approval; and (c) keep TCAM informed of its efforts regarding this Section. Notwithstanding the foregoing, TCAM is not obligated to perform any obligations to Supplier under this Agreement until Supplier has provided TCAM with satisfactory evidence that this approval, notification or registration is not required or that it has been obtained.

 

3. Manufacture and Supply of the AQP Products.

 

(a)    Orders. As applicable, each Order, in substantially the form attached hereto as Schedule A, shall specify: (a) the type and quantity of AQP Products, (b) the manufacturing location(s) of the AQP Products; (c) the unit prices, Fees and payment terms; (d) any packaging and delivery instructions and the delivery schedule; and (e) the quality assurance protocols and any approval procedures. In addition, each Order may also include additional terms and conditions related to such specific Order that will be binding upon mutual agreement of the Parties. The Parties agree that the terms of an Order shall prevail over any conflicting provision in this Agreement. Any additional or different terms or conditions in any acknowledgment or other instrument or response of Supplier shall be deemed objected to by TCAM without need of any further or additional notice of objection, and such additional or different term shall be of no effect or in any way binding upon TCAM.

 

(b)    Multiple Purchases under an Order. If TCAM contemplates multiple purchases of the AQP Products under a particular Order, TCAM may, from time to time, submit firm written purchase orders identifying the quantity and type of the AQP Products, the required delivery date(s), and the delivery instructions (each, a “Purchase Order”). Supplier agrees to notify TCAM whether it is able to ship the AQP Products on the schedule set forth in the applicable Purchase Order within three (3) business days from receipt of such Purchase Order. In cases where Supplier provides such notice that it cannot meet the delivery schedule, it shall propose an alternate schedule that will be subject to acceptance or cancellation of the applicable Purchase Order by TCAM within a reasonable period of time following receipt of Supplier’s schedule proposal. A Purchase Order shall be deemed accepted by Supplier unless Supplier provides written notice of rejection within five (5) days of its receipt of the Purchase Order. All such Purchase Orders will be deemed to be Orders and shall be subject to the terms of this Agreement.

 

(c)    Order Modifications or Cancellations. At any time prior to Supplier’s delivery of the AQP Products, TCAM may, upon written notice, modify an Order to (a) correct typographical or clerical errors; (b) change the location for delivery or any shipping instructions; (c) modify the quantity; (d) modify the delivery date, and/or (e) order items which are of a superior quality, enhancements to, or new options of the AQP Products set forth in the Order. In addition to the foregoing, TCAM may cancel all or any portion of an Order, without charge or penalty, at any time prior to Supplier’s tender of the applicable AQP Products to TCAM or another carrier for delivery.

 

(d)    Initial Order. Supplier hereby acknowledges that providing the AQP Products to TCAM is essential to the ongoing operations of the Platform. Supplier agrees to provide the AQP Products no later than six (6) months from the date the Platform is deployed. For purposes of this Agreement, “deployed” or “deployment” shall mean release of the Platform to the general public whereby potential clients and customers will be able to access the Platform to purchase AQP Products.

 

3

 

 

4. Shipments of the AQP Products.

 

(a)    Packaging and Shipping. Supplier shall properly pack, mark and ship the AQP Products in accordance with the GALT Standards. Supplier shall promptly provide to TCAM, in such form and detail as TCAM may request, all relevant shipment documentation. Supplier shall remain responsible for any damage or loss caused by the improper packaging or crating of the AQP Products or any failure of Supplier to comply with the applicable packaging or shipping instructions.

 

(b)    Transportation Charges. Unless otherwise set forth in the applicable Order, Supplier agrees to pay all transportation charges incurred in delivering the AQP Products to the applicable destinations either as noted in an Order or as indicated in a separate writing from TCAM to Supplier. On behalf of TCAM, and as TCAM’s agent, Supplier agrees to procure insurance for the full value of all AQP Products from the time that the AQP Products are identified until the time of actual receipt of the AQP Products by or on behalf of TCAM. The cost of this insurance shall be borne by Supplier. Supplier shall be responsible for all transportation costs for return of rejected AQP Products and their replacement and for any return or replacement of defective AQP Products furnished under the warranty.

 

(c)    Delivery Terms. Supplier shall, at its sole cost, be responsible for all manufacturing, and transporting of the AQP Products. Supplier will deliver the AQP Products in accordance with written instructions from TCAM to Supplier. TIME OF DELIVERY, QUANTITY AND DELIVERY LOCATION ARE OF THE ESSENCE UNDER THIS AGREEMENT. Supplier shall immediately notify TCAM if it has any reason to believe that any AQP Products will not be delivered in accordance with any of the schedule or delivery terms set forth in the written instruction. If Supplier fails to deliver as and when specified, TCAM may, in TCAM’s sole discretion and at Supplier’s sole cost and expense: (a) approve a revised delivery date or delivery terms; (b) require an expedited or premium shipment; or (c) cancel the Order or any part thereof and purchase elsewhere and hold Supplier accountable for any excess cost resulting therefrom without prejudice to its other rights. For the avoidance of doubt, delivery times will be measured at the time that AQP Products are received at the delivery location identified in the written instruction. Unless otherwise provided in the applicable Order or written instruction, all shipments will be delivered FOB destination (AQP Product receiving point), regardless of whether Supplier or AQP pays for actual freight delivery charges. Supplier bears all risks of loss or damage during shipments to the applicable destinations, including any return shipments in the event of any rejections or returns. Unless otherwise expressly agreed to by TCAM in writing, Supplier shall not make overrun or underrun shipments of AQP Products to TCAM. In the event of an overrun shipment, the overrun will be considered free of charge.

 

5. Quality Control.

 

(a)    Quality Assurance and Testing. Supplier shall apply quality control and quality assurance procedures and in-plant quality control checks for the AQP Products in accordance with industry best practices, and prior to shipment, Supplier will, at its sole cost, perform a full panel of testing on all AQP Products to the extent deemed necessary by TCAM or as otherwise required to confirm compliance with the GALT Standards.

 

(b)   TCAM Verification. All batches of AQP Products are subject to TCAM’s inspection and approval or rejection notwithstanding TCAM’s prior receipt of or payment for the AQP Products. TCAM shall have a reasonable period of time following delivery of the AQP Products to inspect and test any received batch of Products; provided, however, that TCAM shall be under no duty to inspect the Productspurchased hereunder before their use or resale, and any processing, manufacture or resale shall not constitute an acceptance of Products or a waiver of any claim. In addition to the approval and testing processes set forth in this Agreement and the applicable Order, TCAM may request, at any time during the Term of this Agreement, that Supplier submit to TCAM representatives certain production samples for evaluation and testing purposes as TCAM deems necessary to determine whether such samples conform to the GALT Standards. All samples shall become the property of TCAM.

 

4

 

 

(c)    Non-Conforming Products. Supplier shall not knowingly ship to or invoice TCAM for any batches of the AQP Products that, in whole or in part, do not conform with the GALT Standards (each such AQP Product, a “Non-Conforming Product”). TCAM reserves the absolute right to reject and refuse or revoke acceptance of any Non-Conforming Products. If TCAM or any TCAM Party receives a Non-Conforming Product, TCAM may reject the Non-Conforming Product by providing Supplier with written notice of the rejection, and Supplier will, as directed by TCAM, either: (a) credit TCAM’s account for any amounts previously paid for the Non-Conforming Product or (b) replace the Non-Conforming Product with an AQP Product that complies with the GALT Standards at no additional cost as soon as practicable, but in any event within fifteen (15) days following the notice of such Non-Conforming Product.

 

(d)    Certain Changes. Supplier may not make any changes with respect to the AQP Products without TCAM’s advance written approval, which may be withheld in TCAM’s sole discretion, and any such prohibited changes include, but are not limited to (a) the processes or procedures used by Supplier in the production of the AQP Products and (b) the composition, fit, form, function or appearance of the Products. Notwithstanding the foregoing, if Supplier learns of a possible change to the AQP Products that may reduce costs, improve quality, or otherwise be beneficial to TCAM, Supplier shall promptly notify TCAM of the possible change.

 

6. Fees and Payment.

 

(a)    Pricing. The Fees to be paid by TCAM are set forth in the applicable Order. The Fees are firm and not subject to increase for any reason, including changes in market conditions, increases in raw materials, labor or overhead costs or fluctuations in production volumes. If the Fees are omitted on any Order, the Parties agree that the AQP Products shall be billed at the price last quoted or paid, or the prevailing market price at time of delivery, whichever is lower, unless otherwise specified. Unless otherwise expressly agreed to by TCAM in an Order, the Fees shall be inclusive of any Taxes, third party testing, packaging materials, packing, crating, boxing, shipping, insurance, importation and delivery of the Products.

 

(b)    Payment and Invoices. TCAM agrees to pay to Supplier all undisputed and properly invoiced amounts in accordance with the payment terms identified in the applicable Order, but in no case before TCAM receives and, as applicable, accepts the AQP Products. Supplier shall only be entitled to charge TCAM for the Fees specifically authorized in the Order, and a separate invoice must be rendered for each batch of Products purchased by TCAM pursuant to the applicable Order. Each invoice must include TCAM’s order number, batch number(s), and quantities, invoicing terms and must be delivered to TCAM no later than the day following delivery, with a bill of lading if shipment is made by common carrier. Any invoice submitted without an Order number or the proof of delivery will not be processed. TCAM shall have no obligation to pay for any AQP Products not invoiced within ninety (90) days following delivery of AQP Products in accordance with this Agreement.

 

5

 

 

(c)    Disputes. TCAM reserves the right to contest any invoice, and may, without such action constituting an event of default, withhold payment of that portion of any charges that TCAM disputes in good faith; provided, however, that payment of any invoice shall not waive TCAM’s right to later contest such invoice, in whole or in part. In the event of any dispute between TCAM and Supplier regarding any payments under this Agreement, Supplier agrees to continue performing its obligations while such dispute is being resolved, unless and until this Agreement terminates, and for clarity, Supplier will not have the right to withhold supply of the AQP Products during the dispute resolution process.

 

7. Term; Termination; Suspension.

 

(a)    Term. Unless earlier terminated in accordance with the terms of this Agreement, the term of this Agreement shall commence on the Effective Date and continue for a period of three (3) years (“Initial Term”) and shall automatically renew for successive one (1) year terms (“Renewal Term”, and together with Initial Term, the “Term”), unless either Party, in its sole discretion, provides written notice to the other Party at least ninety (90) days prior to the expiration of the then-current term that the Agreement will not renew. Notwithstanding the foregoing, the Agreement will survive so long as there is an Order in effect between the Parties that was entered into prior to the termination or expiration of the Agreement.

 

(b)    Termination for Convenience. TCAM may terminate this Agreement and/or any Order at any time and for any or no reason by giving a written notice of termination thirty (30) days in advance to Supplier.

 

(c)    Termination for Cause. If either Party breaches a material obligation of this Agreement and the breaching Party fails to cure such breach within thirty (30) days upon receipt of notice of such breach, then the non-breaching Party may terminate this Agreement and/or any Order. In addition to the foregoing, either Party may terminate this Agreement and all Orders if the other Party becomes insolvent, is unable to pay its debts as they mature or is the subject of a petition in bankruptcy, whether voluntary or involuntary, or of any other proceeding under bankruptcy, insolvency or similar laws; or makes an assignment for the benefit of its creditors; or is named in, or its property is subject to a suit for appointment of a receiver; or is dissolved or liquidated.

 

(d)    Termination Upon Change of Control. TCAM may, upon twenty (20) days written notice, terminate this Agreement in the event: (a) there is a change of ownership of Supplier (i.e., entering into a binding agreement for purchase or sale by one person or other entity) of fifty percent (50%) or more of Supplier’s voting shares or securities; (b) there is an entering into a binding agreement for acquisition or transfer of a controlling interest in Supplier; or (c) there is an entering into a binding agreement for any investment in Supplier by a competitor of TCAM or an investment in a competitor by Supplier.

 

(e)    Termination Upon Failure to Satisfy Initial Order. As set forth in Section 3(d), supplying the AQP Product to TCAM is essential to the ongoing operations of the Platform. If GALT fails to meet the obligations set forth in Section 3(d), TCAM may immediately terminate this Agreement and/or any Order. In addition to the foregoing, if this Agreement is terminated pursuant to this Section 7(e), TCAM may utilize third party suppliers or manufacturers to satisfy the Initial Order.

 

(f)    Effect of Termination. Except as otherwise set forth in this Section 7, upon termination or expiration of this Agreement, each Party shall immediately return to the other Party all Confidential Information and data (including all copies thereof) then in its possession, custody, or control including, without limitation: (a) all technical materials and business plans supplied by a Party and (b) the GALT Materials and any manuals and documentation for the GALT Materials and AQP Products. Upon termination or expiration of this Agreement, Supplier will deliver all AQP Products and packaging relating to the AQP Products in TCAM’s inventory and/or as ordered by TCAM prior to the expiration or termination hereof, and all terms and conditions of this Agreement will apply to such performance. Termination of the Agreement shall not relieve the defaulting Party of any obligation accruing with respectto the Agreement prior to such termination. In no event shall TCAM be liable to Supplier for any costs, claims, losses, damages or liabilities including, without limitation, loss of anticipated profits, as a result of any termination of this Agreement. Any termination or expiration of this Agreement will not terminate any Order then in effect unless otherwise expressly stated in the relevant notice of termination. Any terms in this Agreement which by their nature must survive after the Term to give their intended effect shall be deemed to survive termination or expiration of this Agreement.

 

6

 

 

(g)    Suspension. TCAM may direct Supplier to suspend performance under this Agreement for any reason at any time by issuing a stop work order. If TCAM subsequently lifts the stop work order and the stop work order resulted in a decrease in the cost of or a change in the time required for the performance under this Agreement or an Order, the Parties will negotiate an equitable adjustment to the Fees and delivery schedule, as applicable. If a stop work order results in a termination, such termination shall be subject to this Section 7.

 

8. Representations and Warranties.

 

(a)    Supplier Representations and Warranties. Supplier represents, warrants, and covenants that: (i) the Agreement is the valid and binding obligation of Supplier, enforceable against Supplier in accordance with its terms; (ii) it has obtained and shall continue to maintain all licenses, permits and approvals required by any government applicable to the performance of its obligations under this Agreement; (iii) it is and shall continue to be in compliance with all applicable laws and regulations, including without limitation all occupational health, safety and labor laws, codes of practice and local industry practice; (iv) it is the sole and exclusive legal and beneficial owner of each item of Supplier’s Intellectual Property Right and has the valid right to use all other Intellectual Property Rights used in or necessary for the purposes set forth in this Agreement; (v) it covenants to comply with all laws and regulations of federal, state, regional, local, and other governmental bodies in the United States and abroad applicable to Suppliers rights and obligations under this Agreement; (vi) there are no agreements (written or oral), understandings, laws or other restrictions of any kind to which Supplier is a party or subject, that would prevent or restrict Supplier’s execution, delivery, or performance of this Agreement; and (vii) it has provided to TCAM all necessary labels, disclosures and disclaimers to enable TCAM to sell the AQP Products in compliance with all laws and regulations of the applicable jurisdiction where such AQP Products are sold.

 

(b)    AQP Product Warranty. Supplier represents and warrants that all AQP Products will: (a) be manufactured, tested, imported, sold, shipped, packaged and labeled in accordance with all applicable laws; (b) be new and unexpired; (c) free from defects in design, materials, and workmanship; (d) conform to the GALT Standards contained in the Agreement and the Order; and (e) be fit for the purposes intended. Supplier acknowledges and agrees that these representations and warranties shall survive the inspection, testing, acceptance and/or use of the AQP Products by the TCAM Parties.

 

(c)    Applicability. The foregoing warranties shall be in addition to any other warranties, whether express or implied, in the Agreement or as otherwise available to TCAM under applicable law, and Supplier shall be responsible for all liabilities, costs and expenses arising out of any failure of Supplier to meet the representations and warranties contained herein. Supplier agrees that the foregoing warranties shall extend to TCAM and any TCAM Parties, and each of its and their customers, distributors, dealers and agents and to the users and consumers of the AQP Products. The warranties set forth in this Agreement and any Order shall remain in effect (a) for a period of one (1) year after the later of final acceptance of the AQP Products or any discovery of a defect by TCAM or (b) for such longer period as provided under applicable law.

 

9. Audits and Inspections.

 

(a)    Contract Records. Supplier shall maintain all usual and proper records and books of account relating to this Agreement in accordance with generally accepted accounting principles for a period of seven (7) years following termination or expiration of this Agreement.

 

7

 

 

(b)    Operational Audit. Supplier shall permit and fully cooperate with TCAM and any TCAM Party, and each of their designated representatives, upon twenty-four (24) hours’ notice, to enter Supplier’s facilities and any other location where the AQP Products are manufactured, packaged, or stored in order to: (a) audit and make copies of any books and records applicable to Supplier’s business with TCAM and (b) inspect such premises, the workforce, and any machinery used for the manufacture, packaging, or storage of the AQP Products.

 

(c)    General Procedures. TCAM and Supplier will meet to discuss any errors or omissions disclosed by the audit and any aspects of the manufacturing, packaging and storage of AQP Products that may need to be changed or improved. Supplier shall make prompt adjustment to compensate for any errors or omissions disclosed by such audit and make any change or improvement as requested by TCAM or a TCAM Party.

 

(d)    Response to Deficiencies. If any deficiency discovered during the audit and/or any non-conformity has a reasonable potential to risk the timely completion of an Order or is not corrected within thirty (30) days following Supplier’s receipt of TCAM’s written notice, TCAM will have the right to terminate this Agreement or the applicable Order in whole or in part.

 

10. Indemnification.

 

(a)    Response to Deficiencies. If any deficiency discovered during the audit and/or any non-conformity has a reasonable potential to risk the timely completion of an Order or is not corrected within thirty (30) days following Supplier’s receipt of TCAM’s written notice, TCAM will have the right to terminate this Agreement or the applicable Order in whole or in part.

 

(b)    Indemnification. Supplier shall defend, indemnify, and hold harmless TCAM and any TCAM Party and their respective Affiliates and their respective directors, officers, employees, agents, and customers (collectively, the “TCAM Indemnitees”) from and against any and all claims, liabilities, damages, losses, judgments, authorized settlements, costs and expenses (including without limitation, reasonable attorney’s fees) resulting from, arising out of or in connection with (a) any alleged or actual intellectual property infringement or misappropriation; (b) the delivery, condition, manufacture, purchase, use, sale, import, distribution or other transfer of AQP Products purchased hereunder; (c) any breach or alleged breach of this Agreement by Supplier or its personnel; (d) any actual or alleged bodily injury, death of any person or damage to real or tangible personal property caused by the acts or omissions of Supplier or its personnel or arising out of or resulting from the development, manufacture or commercialization of any AQP Products; (e) any actual or alleged negligence, gross negligence, bad faith or intentional or willful misconduct of Supplier or its Affiliates in the performance by Supplier of its obligations hereunder; (f) any product liability claim directly or indirectly related to the AQP Products; (g) any actual or alleged claim brought against TCAM by the Federal Drug Administration or any actual or alleged failure by Supplier or its personnel to comply with any applicable laws, rules, or regulations of any jurisdiction in which AQP Products are sold; or (h) any actual or alleged failure by Supplier to comply with GALT Standards.

 

(c)    Intellectual Property Indemnification. In addition to the foregoing, if any AQP Product becomes or in Supplier’s reasonable opinion is likely to become, the subject of any claim for infringementor misappropriation, Supplier shall, at TCAM’s option and Supplier’s expense: (a) procure for TCAM the right to continue using such AQP Product or (b) replace or modify such AQP Products so that it becomes non-infringing while still providing substantially the same functionality. If the foregoing is not possible within a commercially reasonable time frame, then Supplier shall refund the full amount paid by TCAM for such AQP Product, without prejudice to any other remedies that are available to TCAM.

 

8

 

 

11. Limitation of Liability. TCAM’S TOTAL LIABILITY FOR ANY CLAIMS ARISING UNDER THIS AGREEMENT SHALL NOT EXCEED THE TOTAL FEES PAID OR PAYABLE UNDER THE ORDER GIVING RISE TO SUCH CLAIM. THIS LIMITATION OF LIABILITY IS CUMULATIVE AND NOT PER INCIDENT. IN NO EVENT SHALL TCAM BE LIABLE TO SUPPLIER FOR ANY INCIDENTAL, SPECIAL, INDIRECT, EXEMPLARY, PUNITIVE OR CONSEQUENTIAL DAMAGES, LOST REVENUE, LOST PROFITS, OR LOST OR DAMAGED DATA, HOWEVER CAUSED AND WHETHER ARISING IN CONTRACT, TORT (INCLUDING NEGLIGENCE), OR OTHERWISE, EVEN IF A PARTY OR ITS SUPPLIERS HAVE BEEN INFORMED OF THE POSSIBILITY THEREOF.

 

12. Intellectual Property.

 

(a)    License to GALT Materials. Subject to the terms of this Agreement and any GALT Standards, Supplier hereby grants to TCAM, during the term of the applicable Order, a limited, non-exclusive, revocable, non-transferable, non-sublicensable, license to use and create derivative works of the GALT Materials solely to the extent necessary to produce and supply the AQP Products to TCAM in accordance with the GALT Standards. Supplier shall advise TCAM promptly if Supplier becomes aware of any unauthorized use of the Intellectual Property Rights or of any similar mark or design by any person or of any claim that the AQP Products infringe the Intellectual Property Rights, moral or other rights of any third party.

 

(b)    New Intellectual Property and Developed IP. Supplier irrevocably transfers, conveys, and agrees to assign, and hereby does assign, its entire worldwide right, title and interest in and to any New Intellectual Property and any Intellectual Property Rights that relate to any new AQP Products that may be jointly conceived by or on behalf of the Parties pursuant to an Order (“Developed IP”) to TCAM. Supplier agrees to execute such documents, applications, and conveyances and to supply information as TCAM reasonably requests to permit TCAM to protect, perfect, register, record and maintain its rights and ownership in the New Intellectual Property and any Developed IP throughout the world. TCAM shall have the sole right to file any applications for protection of Intellectual Property Rights for any Developed IP, worldwide. Without limiting the foregoing, TCAM shall have the exclusive right to commercialize, prepare and sell products based upon, sublicense, prepare derivative works from, or otherwise use or exploit the rights owned by TCAM pursuant to this Section.

 

13. Confidentiality

 

(a)    Scope of Confidentiality. As used herein, “Confidential Information” means all confidential and proprietary information of a Party (“Disclosing Party”) disclosed to the other Party (“Receiving Party”), whether orally or in writing, that is designated as confidential or that reasonably should be understood to be confidential given the nature of the information and the circumstances of disclosure, including but not limited to the terms of this Agreement, any subsequent agreement or Order entered into between Supplier and TCAM, and any other information obtained by the Receiving Party concerning the Disclosing Party’s operations that may include valuable, proprietary, and confidential matter or information relating to trade secrets, concepts, formulas, product configurations, designs, specifications, manufacturing processes, operational processes, equipment suppliers, customers, employees, research developments, inventions, engineering, marketing, product recipes, product processing methods (standard operating procedures), merchandising, purchasing, finances and other information of a valuable, proprietary, and confidential nature which is owned by the Disclosing Party or one of its Affiliates and which is the basis for the business conducted by the Disclosing Party and its Affiliates. Confidential Information shall not include any information that: (a) is or becomes generally known to the public without breach of any obligation owed to the Disclosing Party; (b) was known to the Receiving Party prior to its disclosure by the Disclosing Party without breach of any obligation owed to the Disclosing Party; (c) was independently developed by the Receiving Party without breach of any obligation owed to the Disclosing Party; or (d) is received from a third party without breach of any obligation owed to the Disclosing Party.

 

9

 

 

(b)    Confidentiality Obligations. Any Confidential Information shall be used by the Receiving Party pursuant to the terms and for the purposes of this Agreement. Each Party agrees to protect the confidentiality of the Confidential Information of the other Party using the same standard of care that it protects the confidentiality of its own proprietary and confidential information of like kind (but in no event using less than reasonable care). Supplier acknowledges and agrees that it will not make copies or permit copies to be made of any drawings or other data without the prior written consent of TCAM. The Receiving Party agrees that any breach of this Section by the Receiving Party or its employees shall cause irreparable injury to the Disclosing Party, that the disclosing party shall be entitled to specific performance and injunctive or other equitable relief as a remedy for any such breach, and that the Receiving Party agrees to waive any requirement for the securing or posting of any bond in connection with such remedy.

 

(c)    Return of Confidential Information. Upon the expiration or the earlier termination of this Agreement, the Receiving Party shall promptly return all Confidential Information and any copies thereof that it has received under this Agreement.

 

14. Insurance.

 

During the Term of this Agreement and for a period of three (3) years after termination or expiration thereof, unless otherwise agreed in the Order, Supplier shall obtain and maintain, at its own expense (a) Worker’s Compensation insurance in compliance with the statutory requirements for worker’s compensation of the state or states in which it has employees performing any work related to this Agreement; and (b) Commercial General Liability insurance, including contractual liability and product liability, with limits of no less than one million dollars ($1,000,000) per occurrence and in the aggregate. Such policy or policies of insurance shall: (i) name TCAM as an additional party insured; (ii) provide for a waiver of all subrogation rights against TCAM ; (iii) not exclude cross-liability; and (iv) provide that TCAM shall receive not less than thirty (30) days’ notice of any material modification, non-renewal or cancellation of coverage. Upon TCAM ‘s request, Supplier shall provide TCAM with a certificate of insurance evidencing the insurance coverage specified in this Section.

 

15. Miscellaneous.

 

(a)    Subcontracting. Supplier may not subcontract any of its obligations under this Agreement except with TCAM ‘s prior written consent, which may be withheld in TCAM’s sole discretion. For all approved subcontractors, Supplier shall: (a) enter into an separate agreements with its subcontractors with terms and conditions no less restrictive than those set forth herein to ensure that its subcontractors are able to adhere to and comply with the obligations assumed by Supplier under this Agreement; (b) closely monitor all work performed by its subcontractors and prohibit such subcontractor from further subcontracting any part of its work without TCAM’s express prior written consent; (c) ensure that its subcontractors do not attempt to contact any TCAM Party; and (d) remain solely responsible and liable for all acts and omissions of such subcontractor as if performed by Supplier and provide the same remedies to TCAM if a subcontractor fails to comply with any terms hereunder.

 

(b)    Publicity. Unless otherwise permitted herein, Supplier shall not make any statement in any press release, advertising, marketing or promotional materials concerning the transactions contemplated under this Agreement, or make any public statement that includes the name of TCAM or any of the TCAM Parties, or otherwise use the name of TCAM or any of the TCAM Parties in any public statement or document, without the prior written consent of TCAM, except as may be required by law, regulation, including SEC regulation, or order of a governmental agency or court, in which case Supplier shall use reasonable efforts to obtain the approval of TCAM as to form, nature, and extent of the public announcement or public statement prior to issuing the public announcement or public statement.

 

10

 

 

(c)    Non-Compete. Supplier hereby acknowledges and agrees that it may be exposed to a significant amount of Confidential Information concerning TCAM’s business methods, operations and customers during the Term of this Agreement, that such information might be retained by Supplier in tangible form or simply retained in Supplier’s memory, and that the protection of TCAM’s exclusive rights to such Confidential Information, trade secrets and customer or client relationships can best be ensured by means of a restriction on Supplier’s activities during and after the termination of this Agreement. Therefore, Supplier agrees that for the duration of this Agreement and for a period of one (1) year after termination of the Agreement, Supplier shall not solicit, divert or initiate any contacts with (or attempt to solicit, divert or initiate contact with) any customer or client of TCAM, disclosed to Supplier hereunder, for any commercial or business reason whatsoever. In addition to the foregoing, Supplier shall not, at any time, use any Confidential Information of TCAM to manufacture or sell AQP Products or other goods or products that are similar to or competitive with the AQP Products. Additionally, Supplier will not solicit, offer work to, employ, or contract with, directly or indirectly, any of TCAM’s or TCAM Party’s employees or subcontractors during the Term and for one (1) year thereafter, unless such recruitment results from a bona fide recruitment process and such position has been advertised externally.

 

(d)    Execution. Each Party hereby represents and warrants that it is not subject to any agreements or restrictions that would prohibit such Party from entering into this Agreement and carrying out the transactions contemplated by this Agreement in accordance with the terms hereof.

 

(e)    Force Majeure. Any delay or failure of either Party to perform its obligations under this Agreement will be excused to the extent that the delay or failure was caused directly by an event beyond such Party’s control, without such Party’s fault or negligence and that by its nature could not have been foreseen by such Party or, if it could have been foreseen, was unavoidable (which events may include natural disasters, embargoes, explosions, riots, wars or acts of terrorism) (each, a “Force Majeure Event”). Supplier’s financial inability to perform; changes in cost or availability of materials, components or services or market conditions; global, national, or local public health emergency or disease outbreak (including, without limitation, COVID-19 (a/k/a the 2019 Novel Coronavirus); or supplier actions or contract disputes will not excuse performance by Supplier under this Section. Supplier shall give TCAM prompt written notice of any event or circumstance that is reasonably likely to result in a Force Majeure Event, and the anticipated duration of such Force Majeure Event. Supplier shall use all diligent efforts to end the Force Majeure Event, ensure that the effects of any Force Majeure Event are minimized and resume full performance under this Agreement.

 

(f)    Export. Supplier shall prepare, maintain and, to the extent that applicable law, regulation or customs authority requires it to do so, submit to the applicable customs authorities, all information and documentation that is necessary to comply with the applicable customs and export and import requirements of each country from which the AQP Products will be exported and each country into which they will be imported, and Supplier shall comply with all other applicable customs requirements. Whenever TCAM requests it to do so, Supplier shall promptly furnish to TCAM copies of that information and documentation. Supplier is solely responsible for complying with all technical compliance and country of origin requirements of each country into which the AQP Products are to be imported. Supplier assigns and transfers to TCAM all transferable customs duty and tax drawback or refund rights relating to the AQP Products, including rights developed by substitution and rights that Supplier acquires from its suppliers. Supplier shall promptly inform TCAM of each such right and, upon TCAM’s request, shall promptly provide to TCAM all documents and information that are required for TCAM to obtain each such drawback and refund. If importation of the AQP Products results in the assessment of a countervailing duty on TCAM as the importer, Supplier will reimburse such countervailing duty to TCAM, provided such reimbursement is permitted under applicable laws and regulations.

 

11

 

 

(c)    Compliance with Laws. Each Party shall obtain all licenses, permits and approvals required by any government applicable to the performance of its obligations under this Agreement, and shall comply with all applicable laws, rules, policies and procedures of any applicable government or other regulatory authority. Notwithstanding any other provision of this Agreement, if during the Term hereof (a) any new legislation or regulation enacted by any state/provincial government entity; (b) any guidance, interpretation or position of any proposed, existing, or new legislation or regulation enacted by any state/provincial governmental entity; or (c) any official or informal regulatory group or governmental organization or any other third parties threatens or brings a suit against TCAM claiming that the AQP Products are unlawful or that otherwise prohibits, restricts, or materially limits either Party’s ability to continue performing under the existing terms and conditions of this Agreement within the jurisdiction of that state/province (each, an “Adverse Change”), the Parties agree to negotiate in good faith to make reasonable revisions to this Agreement in order to conform to the Adverse Change to the extent applicable. Upon notice by one Party to the other of such Adverse Change, the Parties agree that they shall actively work together in good faith and using commercially reasonable efforts to resolve the matter within thirty (30) days of such notice (“Adverse Change Notice Period”). In the event that the Parties cannot agree upon renegotiated terms within the Adverse Change Notice Period, then TCAM may terminate the affected Order(s) immediately upon written notice to Supplier.

 

(d)    Assignment. This Agreement will be binding upon and inure to the benefit of the Parties, their respective successors and permitted assigns. Except as specifically provided herein, Supplier shall not assign this Agreement nor any of its rights, interests or obligations hereunder (whether by operation of law or otherwise) without the prior written consent of TCAM. For the purposes of this Section, a reorganization, merger, asset or stock sale, statutory conversion, or a change in control of Supplier shall constitute an assignment. TCAM may assign any of its rights or delegate any of its obligations hereunder. Any purported assignment or delegation in violation of this Section is null and void.

 

(e)    Non-waiver. No waiver of any term or right in this Agreement shall be effective unless in writing, signed by an authorized representative of the waiving Party. The failure of either Party to enforce any provision of this Agreement shall not be construed as a waiver or modification of such provision, or impairment of its right to enforce such provision or any other provision of this Agreement thereafter.

 

(f)    Equitable Relief. Each Party acknowledges that a breach of this Agreement may cause irreparable damage to the other Party and hereby agrees that the other Party shall be entitled to injunctive relief under this Agreement, as well as such further relief as may be granted by a court of competent jurisdiction.

 

(g)    Notices. All notices under this Agreement shall be in writing and shall be given or made by delivery in person, by courier service, by confirmed facsimile, or by registered or certified mail (postage prepaid, return receipt requested) at the addresses set forth herein. Any such notice shall be deemed delivered upon the earlier of actual receipt or three (3) days after deposit of such notice. Any notices to TCAM will be addressed to TCAM with: “Attn: Carol Lin, CEO.”

 

(h)    Attorneys’ Fees. The prevailing Party in any action to enforce this Agreement will be entitled to recover its attorneys’ fees and costs in connection with such action.

 

(i)    Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Texas, without regard to its conflict of laws provisions. The Parties specifically disclaim the application to this Agreement of the UN Convention on Contracts for the International Sale of Products. The Parties agree that any dispute relating to the Agreement must be submitted to mandatory binding arbitration. Such arbitration will be conducted before a single arbitrator, selected by agreement of the Parties, who shall hear and resolve the dispute in the City of Austin, Texas.

 

12

 

 

(j)    Relationship of the Parties. This Agreement shall not be interpreted or construed to create an employment relationship, an association, agency, joint venture or partnership between the Parties or to impose any liability attributable to such a relationship upon either Party.

 

(k)    Severability. If any provision of this Agreement will be held by any court of competent jurisdiction to be unenforceable or invalid, that provision will be limited to the minimum extent necessary so that this Agreement will otherwise remain in effect.

 

(l)    Third Party Beneficiaries. Except as expressly set forth in this Section, this Agreement benefits solely the Parties to this Agreement and their respective permitted successors and permitted assigns and nothing in this Agreement, express or implied, confers any legal or equitable right, benefit or remedy of any nature whatsoever to any third party under or by reason of this Agreement. Notwithstanding the foregoing, the Parties hereby designate each TCAM Party and any end users of the Products as third-party beneficiaries of this Agreement.

 

(m)    Amendments; Waivers. No supplement, modification, or amendment of this Agreement will be binding, unless executed in writing by a duly authorized representative of each Party to this Agreement. No waiver will be implied from conduct or failure to enforce or exercise rights under this Agreement, nor will any waiver be effective unless in a writing signed by a duly authorized representative on behalf of the Party claimed to have waived.

 

(n)    Entire Agreement. Except as otherwise provided herein, this Agreement, including all Orders placed hereunder and the Schedules attached hereto, all of which are incorporated by reference, constitutes the complete and exclusive agreement and understanding between TCAM and Supplier with respect to its subject matter and supersedes all prior or contemporaneous oral or written agreements or understandings relating to the subject matter.

 

(o)    Further Assurances. The Parties agree to execute, acknowledge and deliver such further instruments and all such other incidental acts as may be reasonably necessary or appropriate to carry out the purpose and intent of this Agreement.

 

(SIGNATURE PAGE FOLLOWS)

 

13

 

 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives as of the date first above written.

 

  GOLDEN ALLY LIFETECH GROUP, INC.
     
  By: /s/ Oliver K. Ban
  Name: Oliver K. Ban
  Title: Chief Executive Officer
     
  TCAM ASSET MANAGEMENT, LLC
     
  By: /s/ Benjamin Yeung
  Name: Benjamin Yeung           
  Title: Sole Member and Manager

 

14

 

 

SCHEDULE A

 

Form of Order Form

 

Products:

 

First order: [[●] ([●])] bottles, using 432 ml bottles of Golden Ally’s proprietary water, trademarked AQPWaterTM.

 

Subsequent annual commitment: [[●] ([●])] bottles, using 432 ml bottles of Golden Ally’s proprietary water, trademarked AQPWaterTM for [●] years.

 

Registered Trademarks:

 

  AQPWaterTM

 

Pricing:

 

  [●]

 

Additional Provisions:

 

  Delivery: TCAM will separately provide delivery destinations to Supplier in a written instruction.

 

  Transportation and Labels: Supplier will supply and coordinate creation of delivery address labels

 

 

 

Exhibit 10.2

 

Certain identified information marked with [***] has been excluded from this Exhibit because it is not material and is of the type that the registrant treats as private and confidential

 

STRATEGIC ALLIANCE AGREEMENT

 

This Strategic Alliance Agreement (“Agreement”) is entered into this 12th day of July, 2022 (“Effective Date”) by and between Taucoin Asset Management, LLC, a registered Limited Liability Company formed under the laws of Delaware having an office at 100 Congress Avenue, Suite 2000, Austin, Texas 78701 (“TCAM”), and Golden Ally LifeTech Group, Inc., a Delaware corporation having its principal place of business at 901 S. Mopac Exp, Building 1, Suite 300, Austin, Texas 78746 (“GALT”).

 

W I T N E S S E T H:

 

WHEREAS, TCAM and its related subsidiaries and affiliates is a global financial technology company that develops certain blockchain-based technological solutions for business enterprises;

 

WHEREAS, GALT is a publicly-traded, biotechnology company focusing on the development, manufacturing and distribution of its proprietary AQP water products globally (the “AQP Products”);

 

WHEREAS, TCAM and GALT desire to enter into this strategic alliance agreement for the purpose of: (1) licensing certain intellectual property of GALT to TCAM for purposes of TCAM using such intellectual property in the development and ongoing operations of a blockchain-based technology platform (the “Platform”) to facilitate the sale of AQP Products; (2) providing for collaboration in marketing and selling of the AQP Products through the Platform; and (3) creating go to market opportunities involving services and offerings made available by TCAM and GALT (collectively, the “Alliance”).

 

NOW, THEREFORE, for and in consideration of the foregoing and of the mutual representations, promises, terms, and conditions contained herein, receipt of which is hereby acknowledged, and intending to be bound, TCAM and GALT agree as follows:

 

1. Certain Defined Terms.

 

Confidential Information” means the terms and conditions of this Agreement as well as all documents, software, reports, data, records, forms, trade secrets, Personal Information, and other materials obtained by one Party (the “Receiving Party”) from the other Party (the “Disclosing Party”) or at the request or direction of the Disclosing Party in the course of performance under this Agreement: (i) that have been marked as confidential; (ii) whose confidential nature has been made known by the Disclosing Party to the Receiving Party; or (iii) that due to their character and nature, a reasonable person under like circumstances would treat as confidential. Notwithstanding the foregoing and except with respect to Personal Information, Confidential Information does not include information which: (1) is already known to the Receiving Party with no obligation of confidentiality to any person at the time of disclosure by the Disclosing Party; (2) is or becomes publicly known through no wrongful act of the Receiving Party; (3) is independently developed by the Receiving Party without benefit of, or access to, the Disclosing Party’s Confidential Information; or (4) is received by the Receiving Party from a third party without restriction and without a breach of an obligation of confidentiality.

 

1

 

 

GALT IP” means all IP embodied by or covering the AQP Products, any related proprietary information, methods, formulations, concepts, discoveries, processes, and inventions, and any IP owned (as between the Parties) by GALT existing as of the Effective Date, as well as any developments, enhancements, modifications, inventions, and/or derivative works of any of the foregoing.

 

GALT Services” means GALT’s product and services offerings, other than any system integration services or other services competitive with the TCAM Services.

 

Intellectual Property” or “IP” means any and all patents and patent applications, unpatented inventions, copyrights, author’s rights, works of authorship, moral rights, trademarks, service marks, mask works, trade secrets, software, developments, results, designs, patterns, devices, diagrams, charts, drawings, specifications, documentation, and/or data, along with any and all patent applications (including provisional patent applications), registrations, renewals, continuations, reissues and extensions therefor in the United States and foreign countries.

 

Party” means TCAM or GALT. When used in the plural form, the term means TCAM and GALT collectively.

 

Personal Information” means any information that identifies, relates to, describes, or is capable of being associated with, a particular individual, including, but not limited to, his or her name, signature, social security number, physical characteristics or description, address, telephone number, passport number, driver’s license or state identification card number, insurance policy number, education, employment, employment history, bank account or other financial institution account number, credit card number, debit card number, or financial, tax, medical or health information, or any other sensitive personal information.

 

Platform” means the resulting blockchain-based product developed by TCAM utilizing, in part, GALT’s Intellectual Property to facilitate the sale of AQP Products.

 

Security Incident” means an unauthorized disclosure of, access to, or acquisition, processing, transfer or disposal of, Confidential Information.

 

TCAM IP” means all IP embodied or covered by or covering the Platform, the TCAM Services, any related proprietary information, methods, formulations, concepts, discoveries, processes, and inventions, and any other IP owned by TCAM (as between the Parties) existing as of the Effective Date, as well as any developments, enhancements, modifications, inventions, and/or derivative works of any of the foregoing IP.

 

TCAM Trademarks” means Trademarks owned by TCAM that are set forth on Exhibit B hereto or that TCAM has otherwise authorized GALT, in writing, to use as provided in connection with this Agreement.

 

2

 

 

Trademarks” means trademarks, service marks, trade names, business names, logos, get-up, domain names, rights to sue for passing off and unfair competition, rights in opposition proceedings, and all similar rights in any part of the world including, where such rights are obtained or enhanced by registration, any registration of such rights and applications and rights to apply for such registrations.

 

2. Formation of the Alliance

 

2.1 Alliance Formation; Purpose. The Parties hereby form the Alliance with the primary purpose of developing the Platform (a) to facilitate the marketing and sale of AQP Products, including GALT’s proprietary bottled water product based on research related to aquaporins (the “AQPWaterTM”); (b) to identify opportunities to enable the Parties to jointly market the Platform and the AQP Products; (c) to sell licenses to clients providing for access to the Platform (the “Membership”) on the terms and subject to the conditions set forth in this Agreement.

 

2.2 Marketing Activities. As the Parties may mutually agree, in addition to the direct joint marketing to potential clients, the Parties will cooperate throughout the term of this Agreement in identifying, scheduling and carrying out mutually-agreed upon joint marketing activities, such as (i) identifying and attending appropriate seminars, trade shows and conventions at which they will engage in cooperative marketing and promotional activities, (ii) providing marketing collateral material as reasonably requested (provided such marketing collateral shall be mutually agreed in writing by the Parties), and (iii) where appropriate, making joint presentations or setting up joint booths (or equivalents) at such events as the Parties may mutually agree. The Parties will jointly develop guidelines for marketing and promotional activities prior to each applicable activity.

 

2.3 Approval of Potential Clients. TCAM shall have the right to approve any potential clients to be approached regarding the Platform or the TCAM Services (as defined below), including without limitation, to ensure that offering the Platform to such potential client will not violate any of TCAM’s internal policies and procedures.

 

2.4 Marketing Materials. All joint marketing materials will be reviewed by both Parties and agreed to in writing in a timely manner before being presented to any client or potential client. Invitations and registration pages will inform recipients and registrants that any Personal Information provided by them may be shared between TCAM and GALT. Any such information shared by TCAM and GALT will be subject to the provisions of Section 6 below.

 

2.5 No Restrictions on Other Products or Business of the Parties. Except for any exclusive commitments set forth in this Agreement, each Party is free to conduct its business (including with competitors of the other Party) without the involvement of the other Party. Neither Party shall be restricted from utilizing its own Intellectual Property to develop and sell its own products or services similar to those that might be developed as part of the Alliance, or future enhancements to such products or services.

 

2.6 Ownership Rights in Marketing Materials. Each Party will retain full right, title and interest in and to, and ownership of, marketing and sales materials developed solely by that Party. New jointly developed marketing and sales materials will be jointly owned by both Parties, without any right of accounting (“Jointly Owned Materials”). Neither Party may use any such Jointly Owned Materials without the consent of the other Party. Each Party hereby assigns to the other Party a joint and undivided interest in and to all Jointly Owned Materials.

 

3

 

 

3. Relationship of Parties

 

3.1 Independent Contractor. In performing its obligations under this Agreement, each Party is acting as an independent contractor of the other. Each Party shall have exclusive control of the manner and means of performing its obligations under this Agreement. Each Party shall be solely responsible for the supervision, daily direction and control of its own employees and for the payment of their salaries (including, without limitation, withholding of appropriate payroll taxes), worker’s compensation, disability, and other benefits. Nothing in this Agreement shall be construed as: (i) making either Party the agent of the other; (ii) as either Party granting the right to enter into any contract on behalf of such Party to the other Party; or (iii) as establishing a partnership or joint venture between the Parties. Under no circumstances shall the employees of one Party be deemed to be employees of the other for any purpose. Except in those circumstances where one Party is to act as prime and the other Party is to act as subcontractor with respect to a particular client opportunity as described in Section 3.4, each Party will sign separate contracts with customers for that Party’s products or services containing such terms and conditions as such Party may determine, in its sole discretion.

 

3.2 Financial Commitment of GALT. In addition to any other obligations set forth in this Agreement, GALT agrees as follows:

 

(a) GALT will contribute to TCAM an amount equal to the cost of the ongoing development, maintenance and operations of the Platform; and

 

(b) GALT will contribute to TCAM an amount equal to [***] percent of the Gross Sales Price (defined in Section 5.2 below) for the marketing of the Membership and AQP Products.

 

3.3 Financial Commitment of TCAM. TCAM shall have no financial commitment other than to pay Royalties (as hereinafter defined) as set forth in Section 5.

 

3.4 Obligations of TCAM. In addition to any other obligations set forth in this Agreement, TCAM agrees as follows (collectively, the “TCAM Services”):

 

(a) to design and develop the Platform and have the Platform ready to deploy by the end of July 12, 2022, or such other date as may be mutually agreed upon by the Parties in writing;

 

(b) to develop, market and issue the Membership to potential clients and clients (for the avoidance of doubt, all proceeds related to the issuance and sale of a Membership shall belong to TCAM);

 

(c) to develop a mechanism to facilitate the direct sale of AQP products to potential customers; and

 

(d) to leverage GALT, and potentially a GALT end client (who shall be mutually agreed upon in writing and who shall execute any non-disclosure, confidentiality, or other agreement reasonably related to such testing as either Party may reasonably require as a condition of participation in such testing), as co-development partner(s) to test the product and incorporate feedback throughout the development process.

 

4

 

 

3.5 Obligations of GALT. In addition to any other obligations set forth in this Agreement, GALT agrees as follows:

 

(a) to assist TCAM with the marketing of the Platform and the AQP Products; and

 

(b) to ensure that AQP Products are supplied to TCAM in a sufficient amount to accommodate clients that purchased a Membership to access such AQP Products.

 

3.6 Separate Contracting; Subcontractor Arrangements. It is expected that,

 

notwithstanding the joint marketing activities by the Parties in furtherance of the Alliance, each Party will enter into a separate agreement with the client for the Platform or the TCAM Services, as the case may be; provided, however, that for any relationship with an Alliance client requiring a subcontract agreement between the Parties, the Parties will enter into a subcontractor agreement on such terms as the Parties may agree in writing. Depending on the relationship with the client, one of the Parties will be the prime contractor and the other Party will be the subcontractor.

 

3.7 Representation. Except as otherwise provided herein, neither Party will promote

 

this relationship, use the other Party’s name or logo or represent the relationship or other Party, without the prior written consent of the other Party. It is expected that the Parties will in certain circumstances co-brand service offerings and marketing materials, subject to approval by both Parties in each such Party’s sole discretion.

 

3.8 Trademarks License; Web-Linking.

 

(a) GALT Trademarks License. During the term of this Agreement, and subject in each case to the restrictions set forth in this Agreement, GALT hereby grants to TCAM a limited, revocable, nonexclusive, nontransferable (except as permitted under Section 12.2), paid-up and royalty-free license, without right of sublicense, to use the GALT Trademarks set forth on Exhibit A to this Agreement solely in connection with its Alliance-related activities.

 

i) In using GALT’s Trademarks, TCAM shall: (i) cause the appropriate designation TM or registration symbol ® to be placed adjacent to the Trademarks in each use, as the case may be; (ii) cooperate to maintain the goodwill associated with GALT’s Trademarks; and (iii) state in text on each Web page or document on which the Trademarks are used, or in an accompanying terms of use agreement accessible from such a page, that “Golden Ally LifeTech Group’s Trademarks are the sole property of Golden Ally LifeTech Group and their use here does not imply auditing by or endorsement of Golden Ally LifeTech Group or any of its affiliates or subsidiaries,” or substantially similar language.

 

ii) Use of the GALT logo is subject to review and approval by GALT and compliance with the guidelines set forth on Exhibit A hereof, as the same may be modified by GALT in its sole discretion, provided that GALT will supply to TCAM any such modifications in writing in advance.

 

iii) TCAM agrees that the GALT Trademarks are and will remain the sole property of GALT and agrees not to contest GALT’s ownership of such GALT Trademarks and/or GALT’s right to use or license such GALT Trademarks.

 

5

 

 

(b) TCAM Trademarks License. During the term of this Agreement, and subject in each case to the restrictions set forth in this Section 3.8 and compliance with this Agreement, TCAM hereby grants to GALT a limited, revocable, nonexclusive, nontransferable (except as permitted under Section 12.2), paid-up and royalty-free license, without right of sublicense, to use the logos, trademarks, and service marks of TCAM set forth on Exhibit B to this Agreement (the “TCAM Trademarks”) solely in connection with its Alliance related activities.

 

i) In using the TCAM’s Trademarks, GALT shall (i) cause the appropriate designation TM or registration symbol ® to be placed adjacent to the Trademarks in each use; and (ii) cooperate to maintain the goodwill associated with GALT’s Trademarks.

 

ii) GALT agrees that the TCAM Trademarks are and will remain the sole property of TCAM and agrees not to contest TCAM’s ownership of such TCAM Trademarks and/or TCAM’s right to use or license such TCAM Trademarks.

 

Notwithstanding the foregoing license grants, the Parties will mutually agree in writing to all marketing and promotional materials used in connection with this Agreement (and the manner of display of each such Party’s name on the other Party’s internet site) and shall have the right to object to and thereby prohibit the use of its Trademarks on or in any materials or internet site at any time in its sole discretion.

 

(c) Web-Linking. For the purposes of this Agreement only, each Party hereby grants to the other Party a limited, revocable, non-exclusive, nontransferable (except as permitted under Section 12.2), paid up and royalty-free license, without right of sublicense, to provide a hypertext reference link (“Link”) to the other Party’s World Wide Web site identified by the below Uniform Resource Locators (“URL”), as well as any of the other Party’s URLs which can be accessed via the URL below and which relate to the Platform or TCAM’s Services, as the case may be (“Websites”), in each case solely for and in connection with its Alliance related activities.

 

  https://www.goldenaltg.com
     
  https://www.tcam.com/

 

Each Party reserves the right, in its sole discretion, to require the inclusion of any disclaimers or other wording in conjunction with the use of such Party’s name and/or Link on the other Party’s Website. Each Party shall (i) obtain the other Party’s prior written approval of all references to such Party on such other Party’s Website; and (ii) have the right to object to and thereby prohibit any such references at any time in its sole discretion.

 

(d) Reservation of Rights. Except as expressly granted in this Agreement, each Party shall have no other rights of any kind in the other Party’s Intellectual Property, including without limitation Trademarks, Links, or Websites. Except as expressly granted in this Agreement, nothing in this Agreement is to be construed as granting, by implication or by estoppel or otherwise, a license to any of either Party’s Intellectual Property or proprietary technology. Neither Party shall frame the other Party’s Website. Upon termination of this Agreement, all rights and licenses in and to the Trademarks, Links, and Websites granted hereunder shall terminate, and the Parties shall immediately destroy all copies of the other Party’s Trademarks in its possession (except for anything that may be stored in back up media or other electronic data storage systems, latent data and metadata) and shall cease all use of the other Party’s Trademarks and Links.

 

6

 

 

3.9 Publicity and News Releases. No news release, public announcement, advertisement or publicity concerning this Agreement, any proposals, any resulting contracts, or any subcontracts to be carried out hereunder, shall be released by either Party without the prior written approval of both Parties, except to the extent required by law.

 

3.10 Taxes. Each Party shall bear any and all taxes it incurs as a direct or indirect result of the entry into this Agreement or the rights and obligations under this Agreement, unless the Parties have agreed otherwise.

 

4. Intellectual Property

 

4.1 IP Generally. Except as otherwise expressly provided in this Section 4, any pre-existing Intellectual Property or subsequent independently developed IP brought to the relationship by either Party remains the property of that Party. Intellectual Property brought to the relationship by such Party may only be used with the prior written consent of such Party.

 

4.2 IP Ownership; Development. GALT retains all rights, title and interests in and to the GALT IP, including any and all modifications and improvements thereto and derivatives thereof developed during the Term of this Agreement. GALT hereby assigns, and will assign, to TCAM all right, title, and interest in and to any and all modifications and improvements to and derivatives of the GALT IP. TCAM retains all rights, title and interests in and to the TCAM IP including any and all modifications and improvements thereto and derivatives thereof developed during the Term of this Agreement. TCAM hereby assigns, and will assign, to GALT all right, title, and interest in and to any and all modifications and improvements to and derivatives of the TCAM IP, but for the avoidance of doubt not including any modifications, improvements, and derivatives of the Platform, before or after any assignment thereof to GALT, that TCAM may develop during the Term of this Agreement.

 

4.3 Ownership of the Platform. Subject to the terms of this Agreement, GALT and TCAM agree that TCAM shall own all right, title, and interest in and to the Platform and the Membership, including all right, title, and interest in and to any derivative works, enhancements, or modifications of the Platform and the Membership.

 

4.4 Access and Use Rights for the Platform. Upon deployment of the Platform and concurrent execution by the applicable end client of agreements for access to the Platform and related services, TCAM agrees and hereby grants GALT access and use rights to TCAM’s application environment for the Platform to the extent necessary to enable the use of the Platform by the current and future end clients. The access and use rights granted under this Section 4.4 shall continue for a two (2) year period after TCAM’s first client engagement concerning the Platform.

 

7

 

 

For purposes of this agreement, “deployment” shall mean release of the Platform to the general public whereby potential clients will be able to purchase Memberships for access to the Platform.

 

4.5 No Third Party IP. No Intellectual Property owned by a third party shall be incorporated into the Platform without the prior written consent of TCAM, except with respect to open source software on which blockchain technology relies in general.

 

4.6 No Waiver of Rights; No IP Claims. GALT shall not bring any proceeding, suit or claim of any nature against TCAM wherein GALT claims that the TCAM IP’s use in connection with the Platform in accordance with the terms of this Agreement infringes the GALT IP. The rights and remedies available to TCAM provided for pursuant to this Agreement are in addition to any other rights and remedies provided by law.

 

4.7 No Right of Ownership. Except as otherwise expressly provided in this Section 4, each Party will retain full right, title, interest in and to, and ownership of, its own IP. By virtue of this Agreement, no rights or licenses are granted to either Party except as expressly stated herein. In particular and except as specifically provided herein, nothing in this Agreement shall be construed as granting, or as an undertaking to subsequently grant, to either Party any license, right, immunity, title or interest in or to any IP of the other Party.

 

4.8 Trademarks. Each Party recognizes that the Trademarks of the other Party represent valuable assets of such Party and that substantial recognition and goodwill are associated with such assets. Each Party hereby agrees that it shall not use, or permit a third party to use, the other Party’s Trademarks without the prior written consent of such other Party, unless such use is expressly permitted by this Agreement. Except as expressly stated in this Agreement, nothing in this Agreement shall constitute a license or other authorization entitling a Party to use any other Party’s Trademarks.

 

4.9 No Assignment. Except as expressly stated in this Agreement, nothing in this Agreement shall amount to an assignment, license or transfer of any right or title to or interest in any Intellectual Property owned or licensed by any Party. For the avoidance of doubt, except as expressly stated in this Section 4, all right and title to and interest in any Party’s Intellectual Property rights and the goodwill associated therewith, shall remain with each Party and/or their licensors. Each Party agrees that it will not do anything inconsistent with such ownership and that all use of a Party’s Trademarks by it (should such use be permitted by this Agreement or the other Party in accordance with the terms of this Agreement) shall inure to the owning Party’s benefit and will be on the owning Party’s behalf.

 

5. Fees and Royalties

 

5.1 Access to Platform Pricing. TCAM and GALT shall mutually agree in writing on the pricing for access to the Platform through the sale of a Membership; provided, however, that TCAM may (a) provide a discount of up to twenty percent (20%) of the price agreed upon by the Parties for selling a Membership as may be deemed necessary by TCAM; or (b) create separate and distinct tiers of access to the Platform by pricing a Membership at different values (collectively, the “Price”). Access to the Platform shall be granted to clients that purchase a Membership.

 

8

 

 

5.2 Royalties Payable to GALT. TCAM will pay to GALT a royalty based on the Gross Sales Price (defined below) as follows:

 

(a) With respect to the sale of the Memberships, [***] percent of the Gross Sales Price for all sales of the Membership (the “Membership Royalty”); and

 

(b) With respect to the direct sale of AQP Products, [***] percent of the Gross Sales Price for all direct sales of AQP Products (the “Direct Sales Royalty”) and, together with the Membership Royalty, the “Royalty”).

 

Gross Sales Price” means the Price for accessing the Platform less sales, tariff duties, use, and other taxes directly imposed with reference to particular sales (not including any taxes based on income).

 

(c) The term of the Membership Royalty begins upon TCAM’s first sale of a Membership to a client. The term of the Direct Sales Royalty begins upon TCAM’s first direct sale of an AQP Product to a customer. Each sale of a Membership or an AQP Product will be subject to a Royalty payment. All obligations related to the Royalty payments incurred during the term of this Agreement shall survive the expiration or termination of this Agreement.

 

5.3 Calculation of Royalties. All Royalty payments owed to GALT shall be calculated on a quarterly basis (the “Royalty Period”). (e.g., commencing on the first day of January and ending on the last day of March, except that the first and last calendar periods may be “short” as a result of the effective date of the first sale of any respective access to the Platform).

 

5.4 Payment of Royalties. All Royalties shall be payable no later than ninety (90) days after the termination of the preceding full quarter. Although Royalties calculated against fees billed by TCAM but not yet collected by TCAM from the end client shall be accrued in accordance with Section 5.6, payment of such accrued Royalties shall be included in the quarterly payment immediately following the Royalty Period in which TCAM actually collects the fees on which such accrued Royalties are calculated from the end client and not in any earlier quarterly payment.

 

5.5 Reporting. All sums payable to GALT pursuant to this Agreement shall be paid by TCAM in U.S. Dollars. In the event any Royalties accrue in a currency other than United States Dollars, those Royalties shall be converted to U.S. Dollars at the exchange rate listed in the Wall Street Journal (New York edition) on the day on which TCAM receives payment from the applicable end client. TCAM’s reports shall contain a statement setting forth any such computation of the amount of United States Dollars remitted. For each Royalty Period, TCAM shall provide GALT with a written report showing the client engagements executed during the applicable Royalty Period and the length of each such engagement, a Royalty statement showing the calculation for the Royalties and the total amount due, and such other sales and client related reporting as may be reasonably requested by GALT and in a format agreed upon by the Parties. Such statements shall be furnished to GALT regardless of whether any licenses to access the Platform were sold during the Royalty Period or whether any actual Royalties were owed.

 

5.6 Accrual of Royalties. The Royalties shall accrue upon the sale of the applicable Membership for the specific end client regardless of the time of collection by TCAM. The Membership shall be considered “sold” when such product is leased, consigned, or subject to any other activity that results in an unaffiliated third party acquiring the right to possession or use of the Platform.

 

9

 

 

5.7 Costs and Expenses. Each Party agrees to pay all costs, expenses and other expenditures associated with its Alliance related activities or conducting its duties and obligations under this Agreement, including without limitation, employee and consultant expenses and materials costs, without reimbursement or contribution from the other Party, unless otherwise provided herein or in a separate written agreement. Unless otherwise agreed by the Parties in writing, the costs of all mutually agreed marketing activities will be shared equally between the Parties.

 

6. Confidential Information; Information Security

 

6.1 Protection of Confidential Information. Each Party acknowledges and agrees that it will have access to and become acquainted with Confidential Information of the other Party, and undertakes not to, directly or indirectly, without the prior written consent of such other Party, disclose any Confidential Information of the other Party or the terms of this Agreement except as otherwise expressly set forth below. Each Party shall maintain in confidence all Confidential Information received from the other, either orally or in writing, and shall not to disclose or otherwise make available such Confidential Information to any third party without the prior written consent of the Disclosing Party; provided, however, that Receiving Party may disclose Disclosing Party’s Confidential Information to the Receiving Party’s personnel who need access to such Confidential Information and the Receiving Party may disclose the financial or other terms of the Agreement to its legal and business advisors and to potential investors or purchasers of Receiving Party’s business if such third parties agree in writing to maintain the confidentiality of such Confidential Information or are otherwise bound by professional ethical rules of confidentiality broad enough to encompass such Confidential Information. Receiving Party shall use the same degree of care to protect the Disclosing Party’s Confidential Information as it uses to protect its own Confidential Information of like nature, but in no circumstances less than reasonable care. Each Party shall ensure that any individual or entity receiving Confidential Information for or on behalf of such Party under the Agreement will be bound by substantially similar terms to those contained in the Agreement. Receiving Party shall notify the Disclosing Party promptly of any unauthorized use or disclosure of the Disclosing Party’s Confidential Information and to provide reasonable assistance to such Disclosing Party, and its licensors, in the investigation and prosecution of such unauthorized use or disclosure. Whenever requested by a Disclosing Party, and, in any event, upon the termination of the Agreement, a Receiving Party shall immediately, at its own expense, return to the Disclosing Party in a format reasonably acceptable to the Disclosing Party all manifestations of the Confidential Information (except as otherwise required by applicable law, or contained within backups, metadata, or latent data not used in a production capacity and deleted in the ordinary course) or, at the Disclosing Party’s option, shall destroy, at its own expense all such Confidential Information as the Disclosing Party may designate, and at the request of the Disclosing Party confirm to the Disclosing Party that all such Confidential Information has been destroyed, provided that Receiving Party shall not be liable to Disclosing Party for any inability to perform this Agreement arising out of Receiving Party’s compliance with any request by Disclosing Party to return or destroy Confidential Information under this Agreement.

 

10

 

 

6.2 Disclosure of Client Information. The Parties acknowledge and agree that (a) no Confidential Information of a Party’s clients is to be made available to the other Party under this Agreement, and (b) no Personal Information is contemplated to be provided by a Party to the other, except that each Party shall be permitted to disclose to the other Party business contact information of a Party’s clients or prospective clients provided that it shall have provided all notices and obtained the necessary permission to transfer and disclose such information to the other Party for marketing purposes as contemplated by this Agreement. Neither Party shall make available to the other Party any Personal Information of a Party’s clients or prospective clients that is regulated by the General Data Protection Regulation (EU) 2016/679 unless and until: (i) it provides prior written notice to such other Party; and (ii) the Parties have entered into an amendment to this Agreement in accordance with Section 12.3, which amendment shall include any contractual provisions that are required by applicable law.

 

7. Term and Termination

 

7.1 Term. The term of this Agreement shall commence on the Effective Date and shall continue for a period of three (3) years or until the completion of the final Royalty payment, whichever period is longer, unless earlier terminated in accordance with this Section 7.

 

7.2 Termination for Convenience. Either Party may terminate this Agreement at any time for any reason (including no reason) upon thirty (30) days written notice to the other Party. In the event that GALT terminates this Agreement under this Section 7.2 prior to the deployment of the Platform, then: (i) TCAM shall be entitled to keep the payment received under Section 3.2(a)(i); and (ii) GALT’s license to TCAM under Section 4 shall immediately and automatically terminate. In the event that GALT terminates this Agreement under this Section 7.2 from and after deployment of the Platform, then: (i) TCAM shall be entitled to keep the payment received under Section 3.2(a); (ii) TCAM shall wind down the Platform within thirty (30) days of such termination; (iii) GALT shall reimburse TCAM for any and all costs, expenses and amounts related to winding down the Platform, including any costs related to providing services to clients during the wind-down period; and (iv) ownership of any and all IP shall be returned in accordance with Section 4.

 

7.3 Termination for Cause. Either Party may terminate this Agreement on thirty (30) days prior written notice to the other Party if such other Party is in material breach of the Agreement and such breach is not cured within such thirty (30) day period.

 

7.4 Effect of Termination or Expiration. Except as otherwise expressly provided in this Agreement, upon termination or expiration of this Agreement, the Parties agree that:

 

(a) each Party shall immediately cease use of the other Party’s Intellectual Property and Confidential Information except to the extent necessary to provide continued service to existing customers as of the date of such termination or expiration;

 

(b) subject to Sections 6.1 and 7.4(b), each Party shall immediately return to the other Party or destroy any and all Confidential Information of the other Party, including without limitation, all tangible and electronic copies that include or reference such Confidential Information (except for any such Confidential Information that may be stored in back up media or other electronic data storage systems, latent data and metadata); provided, however, that each Party shall be permitted to retain one (1) copy of the other Party’s Confidential Information for the purpose of identifying the Confidential Information received by such Party; and

 

(c) TCAM shall wind down the Platform within thirty (30) days of such termination and GALT shall reimburse TCAM for any and all costs, expenses and amounts related to winding down the Platform, including any costs related to providing services to clients during the wind-down period.

 

11

 

 

8. Indemnification

 

8.1 Indemnification by GALT. GALT shall indemnify, defend and hold harmless TCAM, and the principals, partners, directors, officers, employees and agents of TCAM (collectively, the “TCAM Indemnitees”) from and against any and all claims, demands, losses, damages, liabilities, lawsuits and other proceedings, judgments and awards, and costs and expenses (including, but not limited to, reasonable outside attorney’s fees and all court costs), in each case arising out of a third-party claim (collectively, “Liabilities”), arising directly or indirectly, in whole or in part, from or occurring as a result of: (a) any intentional breach by GALT of, or willful misconduct of GALT in connection with the performance of, its obligations under this Agreement; (b) any breach of a representation or warranty by GALT, or (c) the infringement, misappropriation, or other violation of any Intellectual Property of a third party (“IP Claim”) arising out of or relating to the GALT IP. GALT further agrees to indemnify, defend and hold harmless TCAM and the TCAM Indemnitees against any Liabilities incurred by TCAM arising in any manner from the failure of GALT, its directors, officers, employees, contractors, subcontractors or agents to comply with any applicable state, federal, or local regulation, law, or rule in connection with the terms and conditions set forth in this Agreement. In no event shall GALT’s indemnification obligations apply to the extent such losses are caused by the negligence or willful misconduct of TCAM or a TCAM Indemnitee.

 

8.2 Indemnification by TCAM. TCAM shall indemnify, defend and hold harmless GALT and the directors, officers, employees and agents of GALT (“GALT Indemnitees”) from and against any and all Liabilities arising directly or indirectly, in whole or in part, from or occurring as a result of: (a) any intentional breach by TCAM of, or willful misconduct of TCAM in connection with the performance of, its obligations under this Agreement; (b) any breach of a representation or warranty by TCAM, or (c) any IP Claim arising out of or relating to the TCAM IP. In no event shall TCAM’s indemnification obligations apply to the extent such losses are caused by the negligence or willful misconduct of GALT or a GALT Indemnitee. TCAM shall have no obligations with respect to any IP Claim to the extent that the IP Claim arises or results from: (i) TCAM’s compliance with GALT’s specific written technical designs or instructions; (ii) modification of the TCAM IP by GALT; or (iii) use of the TCAM IP in combination with products not provided by TCAM or as part of the Platform.

 

8.3 Indemnification Procedures. The indemnified Party shall provide prompt written notification to the indemnifying Party in writing of any claim that may give rise to a claim for indemnification hereunder. The indemnifying Party shall control the defense and settlement of such claim and the indemnified Party shall cooperate with all reasonable requests of the indemnifying Party (at the indemnifying Party’s expense) in defending or settling a claim. The Party not conducting the defense shall nonetheless have the right to participate in such defense at its own expense. The indemnified Party shall have the right to approve the settlement of any claim that imposes any liability or obligation other than the payment of money damages for which the indemnifying Party has accepted responsibility.

 

12

 

 

8.4 Notice. Each Party shall give notice promptly to the other Party if it believes that any third party is violating any patents issued in connection with the Combined Products or if it receives any notice by any third party claiming that such patents infringe or misappropriate any third party intellectual property rights.

 

9. Limitation of Liability

 

9.1 NO CONSEQUENTIAL DAMAGES. EXCEPT FOR ANY INDEMNIFICATION OBLIGATIONS CONTAINED HEREIN, NEITHER PARTY SHALL, UNDER ANY CIRCUMSTANCES, BE LIABLE TO THE OTHER FOR LOSS OF PROFITS, INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES RESULTING FROM OR IN ANY WAY RELATED TO THIS AGREEMENT, TERMINATION OF THIS AGREEMENT OR BREACH BY EITHER PARTY.

 

9.2 ACT OF OTHER PARTY. NO PARTY SHALL BE LIABLE FOR ANY LOSSES, INJURIES, OR DAMAGES CAUSED BY OR ATTRIBUTABLE TO THE ACTS AND/OR OMISSIONS OF THE OTHER PARTY, ITS EMPLOYEES, OR ITS AGENTS.

 

9.3 LIMITATION OF LIABILITY. EXCEPT FOR THE INDEMNIFICATION OBLIGATIONS CONTAINED HEREIN, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY UNDER THIS AGREEMENT (WHETHER IN CONTRACT, TORT, NEGLIGENCE, STRICT LIABILITY, BY STATUTE OR OTHERWISE) FOR AN AMOUNT IN THE AGGREGATE IN EXCESS OF $1,000,000.

 

9.4 WARRANTY DISCLAIMER. EXCEPT AS EXPRESSLY SPECIFIED IN THIS AGREEMENT, ALL REPRESENTATIONS AND WARRANTIES ARE SPECIFICALLY EXCLUDED AND DISCLAIMED BY BOTH PARTIES, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND ANY WARRANTY ARISING BY STATUTE, OPERATION OF LAW, COURSE OF DEALING OR PERFORMANCE, OR USAGE OF TRADE. NEITHER PARTY MAKES ANY WARRANTY AS TO THIRD PARTY SERVICES OR THIRD PARTY MATERIALS. Representations, Warrantees and Covenants

 

10.1 Corporate Representations. As a material inducement for each Party to enter into this Agreement, each Party hereby represents and warrants to as follows:

 

(a) Each Party has the power and authority (corporate or otherwise) to enter into this Agreement and to consummate the transactions contemplated hereby. This Agreement has been duly executed and delivered by each Party and constitutes legal, valid and binding obligations of each Party, enforceable against the other Party in accordance with its terms and conditions.

 

(b) GALT represents and warrants that there are no audits, inspections, actions, suits, claims, investigations or legal, administrative or arbitration proceedings pending or, to its knowledge, threatened against GALT, nor, to its knowledge, does any basis exist therefor, whether at law or in equity, whether civil or criminal in nature or whether before or by any federal, state, municipal, or other governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, which relates to any matter that could significantly impact its ability to enter into this Agreement, to grant the rights granted hereunder, and/or perform its obligations under this Agreement.

 

13

 

 

(c) There are no agreements (written or oral), understandings, laws or other restrictions of any kind to which such Party is a party or subject, that would prevent or restrict such Party’s execution, delivery, or performance of this Agreement or such Party’s participation in the Alliance.

 

10.2 Mutual Covenants. As a material inducement for each Party to participate in the Alliance and/or enter into this Agreement, each Party hereby covenants to the other Party as follows:

 

(a) Each Party hereby covenants to comply with all laws and regulations of federal, state, regional, local, and other governmental bodies in the United States and abroad applicable to such Party’s rights and obligations under this Agreement.

 

(b) The Parties acknowledge that this Agreement contemplates various actions being taken in furtherance of the Alliance by the Parties. No Party shall, without the express prior written consent of the other Party, take any action for or on behalf of or in the name of the other Party, or assume, undertake or enter into any commitment, debt, duty or obligation binding upon the other Party.

 

(c) Each Party is the sole and exclusive legal and beneficial owner of each item of such Party’s Intellectual Property and, has the valid right to use all other Intellectual Property used in or necessary for the purposes set forth in this Agreement, and any other purpose as mutually agreed upon by the Parties, in furtherance of the development of the Platform and the Alliance, in each case free and clear of all liens. To the knowledge of the Parties, the use of such Party’s Intellectual Property in furtherance of the Alliance and in connection with the development, deployment and operation of the Platform and the issuance of the Membership has not infringed, misappropriated or otherwise violated, and does not infringe, misappropriate or otherwise violate, the Intellectual Property rights of any other Person. There is no Action initiated by any other person pending or, to either Party’s knowledge, with respect to such Party’s Intellectual Property, threatened, against such Party concerning any Intellectual Property. To either Party’s knowledge, with respect to such Party’s Intellectual Property, no person is engaging in any activity that infringes, misappropriates or otherwise violates any Intellectual Property.

 

10.3 No Malware or Disabling Devices. TCAM shall employ industry standard anti-malware and anti-virus screening designed to detect and eliminate computer code designed to damage, disrupt, disable, harm or otherwise impede in any manner, the orderly operation of the TCAM IP and/or the Platform (“Malware”). TCAM IP and/or the Platform will not include or introduce into any systems of GALT or any end client any Malware, or any mechanisms designed by TCAM to disable the use or operation of TCAM IP and/or the Platform before the end of any applicable term of use for TCAM IP and/or the Platform under the Agreement. TCAM will not unilaterally, without GALT’s permission or an appropriate judicial order, disable (except at the end of any applicable term of use for TCAM IP and/or the Platform under the Agreement), interfere with, delete, or repossess any TCAM IP and/or the Platform for any reason, except that TCAM may suspend or terminate provision of the Platform with respect to any particular client in accordance with the terms of the agreement between TCAM and such client.

 

14

 

 

11. Audit

 

11.1 TCAM shall maintain accurate books and records to enable the verification of the accuracy of TCAM’s Royalty payments under this Agreement and TCAM’s compliance with its obligations under this Agreement. TCAM shall retain the books and records for each Royalty Period for a rolling three (3) year period. Upon reasonable prior notice to TCAM, GALT shall have access to the relevant books and records under the control of TCAM to conduct a review or audit not more than twice (2X) per calendar year, for the sole purpose of verifying the accuracy of TCAM’s Royalty payments and compliance with this Agreement. The audit may determine, among other issues, whether there has been an underpayment of Royalties and, if so, the amount thereof. Such access shall be permitted during TCAM’s normal business hours during the term of this Agreement and for five (5) years after the expiration or termination of the Agreement. Any such inspection or audit shall be at GALT’s expense; provided, however, that in the event an inspection reveals underpayment by TCAM of ten percent (10%) or more in any audit period, TCAM shall pay the costs of the inspection. In any event, TCAM shall promptly pay to GALT any undisputed underpayment, within thirty (30) days of receipt of such written audit. Notwithstanding the foregoing and for the avoidance of doubt, in no event shall TCAM be required to provide records or facilitate access to information that is not directly related to this Agreement. Any and all information disclosed under this Section 11 shall be deemed TCAM’s Confidential Information subject to Section 6 of this Agreement.

 

12. Miscellaneous

 

12.1 Section Headings; Construction. Section headings contained in this Agreement are inserted for convenience of reference only, shall not be deemed to be a part of this Agreement for any purpose, and shall not in any way define or affect the meaning, construction or scope of any of the provisions of this Agreement. In this Agreement, unless a clear contrary intention appears: (i) where not inconsistent with the context, words used in the present tense include the future tense and vice versa and words in the plural number include the singular number and vice versa; (ii) reference to any person includes such person’s successors and assigns but, if applicable, only if such successors and assigns are not prohibited by this Agreement; (iii) reference to any gender includes each other gender; (iv) reference to any agreement, document or instrument means such agreement, document or instrument as amended or modified and in effect from time to time in accordance with the terms thereof and includes all addenda, exhibits and schedules thereto; (v) “hereunder,” “hereof,” “hereto,” and words of similar import shall be deemed references to this Agreement as a whole and not to any particular Section or Subsection of this Agreement; (vi) “including” (and with correlative meaning, “include”) means including without limiting the generality of any description preceding such term; (vii) any reference to “dollars” means United States Dollars; (viii) all references to “days” refer to calendar days; and (ix) where not inconsistent with the context, the word “or” is not exclusive. This Agreement has been executed in English and the English language version shall control notwithstanding any translations of this Agreement. Unless otherwise expressly permitted under this Agreement, all deliverables will be in English.

 

15

 

 

12.2 Assignments; Binding. Neither Party may assign, transfer or delegate any of its rights, obligations, claims or proceeds from claims arising under or relating to this Agreement (including by operation of law) without the prior written consent of the other Party, which consent may be withheld in the other Party’s sole discretion; provided that, notwithstanding the foregoing, TCAM may assign this Agreement in connection with a Change of Control (as defined below) without the need for such consent, provided further that in the event of a sale of all or substantially all of TCAM’s assets, business or a majority of TCAM’s voting securities or any merger or other change of control with respect to TCAM (each, a “Change of Control”), TCAM shall provide GALT with at least thirty (30) days’ notice (the “Transaction Notice”) prior to the closing of the potential Change of Control transaction. Any purported assignment of this Agreement, or any rights, obligations, claims or proceeds thereunder, without such prior written consent shall be null and void and of no force or effect. The rights and obligations of the assignor pursuant to this Agreement shall be assumed by any assignee with any assignment. Subject to any provisions hereof restricting assignment, transfer and delegation, this Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective successors, heirs, executors, administrators, legal representatives and permitted assigns.

 

12.3 Waivers and Amendments. Any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed, in the case of an amendment, by the Parties hereto, or in the case of a waiver, by the Party against whom the waiver is to be effective. Any Party’s failure to insist upon the strict performance of this Agreement or to exercise any right to remedy shall not be considered a waiver of that Party’s right to insist upon strict performance of this Agreement or a waiver of any right or remedy with respect to any existing or subsequent breach or default. No waiver of any breach of any provision of this Agreement shall constitute a waiver of any prior or subsequent breach of the same, or any prior, concurrent or subsequent breach of any other provisions under this Agreement.

 

12.4 Notices. The addresses of the Parties to this Agreement until changed by either Party by written notice to the other Party are:

 

GALT:

 

Golden Ally LifeTech Group, Inc.
901 S Mopac Exp, Bldg-1, Suite 300
Austin, TX 78746

Attention: Oliver K Ban, CEO

E-mail: oliver.ban@goldenaltg.com

 

Copy to:

 

Nelson Mullins Riley & Scarborough
2 S. Biscayne Blvd., 21st Floor

Miami, FL 33131

Attention: Jackson Hwu

E-mail: jackson.hwu@nelsonmullins.com

 

16

 

 

TCAM:

 

Taucoin Asset Management, LLC
100 Congress Avenue, Suite 2000
Austin, TX 78701

Attention: Carol Lin, CEO

E-mail: carol.lin@tcam.com

 

Copy to:

 

Nelson Mullins Riley & Scarborough, LLP

One Nashville Place, Suite 1100

150 4th Avenue, N

Nashville, TN 37219

Attention: Kevin Tran

E-mail: kevin.tran@nelsonmullins.com

 

Any notice or written statement required hereunder shall be deemed to have been duly given upon the sending thereof by electronic mail, overnight mail, certified mail or nationally recognized courier service to the other Party at the address above or at such latest address as it may have from time to time designated in writing to the other Party in accordance with this Section 12.4.

 

12.5 Force Majeure. The failure of either Party to perform any obligation under this Agreement solely by reason of causes beyond its reasonable control, including but not limited to acts of God, natural disasters, acts, laws, regulations or rules of any government body or governmental agency, war, revolution, invasion, insurrection, riots, mob violence, sabotage or other civil disorders, strikes or other labor disputes (“Force Majeure”), shall not be deemed a breach of this Agreement; provided, however, that the Parties shall promptly meet to determine an equitable solution to the effects of such Force Majeure, and provided further the Party so prevented from complying herewith shall continue to take all reasonable actions within its power to comply as fully as possible herewith and to resume with the least possible delay compliance with its obligations.

 

12.6 Entire Agreement. This Agreement (which includes all exhibits, attachments, schedules and other documents which have been incorporated by reference) constitutes the entire understanding between the Parties hereto with respect to the subject matter hereof.

 

12.7 No Third Party Beneficiaries. Except as expressly stated otherwise, no provisions in this Agreement are intended or shall be construed to confer upon or give any person or entity other than the Parties any rights, remedies, or other benefits under or by reason of this Agreement.

 

12.8 Survival. In addition to any specific terms in this Agreement which contemplate an obligation extending beyond the expiration or termination of the Agreement, any terms which by their nature should survive, shall survive the expiration or earlier termination of this Agreement, including without limitation Sections 4, 6, 7, 8, 9, and 12.

 

17

 

 

12.9 Authority. Each person signing this Agreement represents and warrants that he/she has been duly authorized and has the requisite authority to execute and deliver this Agreement on behalf of such Party.

 

12.10 No Reliance. The Parties represent, acknowledge and expressly affirm that, in entering into this Agreement, they are not relying and have not relied in any way or in any degree whatsoever upon any representation or statement made, or the absence of any representation or statement, by any person or Party or any of their agents, shareholders, representatives or attorneys, with regard to the subject matter, basis or effect of this Agreement or otherwise, other than those representations or statements as specifically and expressly stated in this Agreement.

 

12.11 Counterparts. This Agreement may be executed in one or more counterparts, including by email and facsimile, each of which shall be deemed an original, but all of which together constitute one and the same instrument.

 

12.12 Jointly Drafted. The Parties acknowledge that each has participated in the drafting and negotiating of this Agreement. For purposes of interpreting this Agreement, each provision will be deemed to have been jointly drafted by the Parties. The Parties intend for this Agreement to be construed and interpreted neutrally, in accordance with the plain meaning of its language, and not presumptively construed against any actual or purported drafter of specific language contained in it.

 

12.13 Severability. If any part of this Agreement is contrary to, prohibited by or deemed invalid under applicable law or regulations, such provision shall be inapplicable and deemed omitted to the extent so contrary, prohibited or invalid, but the remainder of this Agreement shall not be invalid and shall be given full force and effect so far as possible.

 

12.14 Governing Law; Alternative Dispute Resolution.

 

(a) This Agreement shall be governed by and construed in accordance with the laws of the State of Texas, without regard to the conflict of laws provisions thereof.

 

(b) Any dispute or claim between the Parties under this Agreement shall be submitted first to non-binding mediation and, if mediation is not successful within 90 days after the issuance by one of the Parties of a request for mediation then to binding arbitration in accordance with the Rules for Non-Administered Arbitration of the International Institute for Conflict Prevention and Resolution (the “IICPR”). Any issue concerning the extent to which any dispute is subject to arbitration, or any dispute concerning the applicability, interpretation, or enforceability of these dispute resolution procedures, including any contention that all or part of these procedures is invalid or unenforceable, shall be governed by the Federal Arbitration Act and resolved by the arbitrators. By operation of this provision, the Parties agree to forego litigation over such disputes in any court of competent jurisdiction.

 

18

 

 

(c) Mediation shall take place at a location to be designated by the Parties using the Mediation Procedures of the IICPR, with the exception of paragraph 2 (Selecting the Mediator).

 

(d) Arbitration shall take place in Austin, Texas and shall be governed by the Federal Arbitration Act, 9 U.S.C. §§ 1, et seq. Party-selected arbitrators shall be selected from the lists of neutrals maintained by either the IICPR or by JAMS, Inc., but the chair of the arbitration panel does not have to be selected from those specific lists. The arbitration panel shall have no power to award non-monetary or equitable relief of any sort except as provided in IICPR Rule 13 (Interim Measures of Protection). Damages that are inconsistent with any applicable agreement between the Parties (including Paragraph 6 above), that are punitive in nature, or that are not measured by the prevailing Party’s actual damages shall be unavailable in arbitration or any other forum. In no event, even if any other portion of these provisions is held to be invalid or unenforceable, shall the arbitration panel have power to make an award or impose a remedy that could not be made or imposed by a court deciding the matter in the same jurisdiction.

 

(e) Either Party may seek to enforce any written agreement reached by the Parties during mediation, or to confirm, enforce or vacate any final award entered in arbitration, in any court of competent jurisdiction, provided that any Party moving to enforce, confirm or vacate any such agreement or award, as the case may be, will file such motion under seal unless prohibited under applicable court rules.

 

(f) Notwithstanding the agreement to such procedures, either Party may seek equitable relief to enforce its rights in any court of competent jurisdiction.

 

19

 

 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives as of the date first above written.

 

Golden Ally LifeTech Group, Inc.   Taucoin Asset Management, LLC
         
By: /s/ Oliver K Ban   By: /s/ Benjamin Yeung
Name: Oliver K. Ban   Name: Benjamin Yeung
Title: Chief Executive Officer   Title: Sole Member and Manager

 

[Signature Page to Strategic Alliance Agreement]

 

20

 

 

Exhibit A

 

GALT Trademarks

 

21

 

 

Exhibit A

 

22

 

 

Exhibit B

 

TCAM Trademarks

 

23

 

 

Exhibit B

 

24

 

 

Exhibit 31.1

 

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Oliver Keren Ban, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Golden Ally Lifetech Group, Inc. for the quarter ended September 30, 2022;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
   
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
   
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;
   
5. The registrant’s other certifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditor and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
   
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 21, 2022   Golden Ally Lifetech Group, Inc.
       
      By: /s/ Oliver Keren Ban                          
        Oliver Keren Ban, Chief Executive Officer (Principal Executive Officer) and Director

 

 

 

Exhibit 31.2

 

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Tak Yiu Cheng, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Golden Ally Lifetech Group, Inc. for the quarter ended September 30, 2022;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
   
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
   
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
   
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;
   
5. The registrant’s other certifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditor and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
   
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 21, 2022   Golden Ally Lifetech Group, Inc.
         
      By: /s/ Tak Yiu Cheng                                
        Tak Yiu Cheng, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

 

 

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Golden Ally Lifetech Group, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the Company’s Chief Executive Officer, Oliver Keren Ban, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 21, 2022   Golden Ally Lifetech Group, Inc.
         
      By: /s/ Oliver Keren Ban                            
        Oliver Keren Ban, Chief Executive Officer (Principal Executive Officer) and Director

 

 

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Golden Ally Lifetech Group, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the Company’s Chief Financial Officer, Tak Yiu Cheng, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 21, 2022   Golden Ally Lifetech Group, Inc.
         
      By: /s/ Tak Yiu Cheng                       
        Tak Yiu Cheng, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)